0001493152-20-005627.txt : 20200401 0001493152-20-005627.hdr.sgml : 20200401 20200401170217 ACCESSION NUMBER: 0001493152-20-005627 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200401 DATE AS OF CHANGE: 20200401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AdvanSource Biomaterials Corp CENTRAL INDEX KEY: 0001011060 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043186647 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11737 FILM NUMBER: 20766107 BUSINESS ADDRESS: STREET 1: 229 ANDOVER STREET CITY: WILMINGTON STATE: MA ZIP: 01887 BUSINESS PHONE: 978-657-0075 MAIL ADDRESS: STREET 1: 229 ANDOVER STREET CITY: WILMINGTON STATE: MA ZIP: 01887 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOTECH INTERNATIONAL INC DATE OF NAME CHANGE: 19960321 10-Q 1 form10-q.htm

 

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)    
[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2019
[  ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                    to                         

 

Commission File No. 0-28034

 

ADVANSOURCE BIOMATERIALS CORPORATION

 

(Name of small business issuer in its charter)

 

Delaware   04-3186647

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

229 Andover Street, Wilmington, Massachusetts   01887
(Address of principal executive offices)   (Zip Code)

 

Issuer’s telephone number (424) 256-8560

 

Securities registered under Section 12(b) of the Exchange Act:

 

None   None
Title of each class   Name of each exchange on which registered

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value per share

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

[  ] Large Accelerated Filer   [  ] Accelerated Filer
[  ] Non-accelerated Filer   [X] Smaller reporting company
[  ] Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [  ] No [X]

 

As of April 1, 2020, 28,262,371 shares of the registrant’s Common Stock were outstanding.

 

 

 

 

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
Item 1 Unaudited Condensed Financial Statements  
  Condensed Balance Sheets at December 31, 2019 (unaudited) and March 31, 2019 3
  Condensed Statements of Operations for the three and nine months ended December 31, 2019 and 2018 (unaudited) 4
  Condensed Statements of Stockholders’ Deficit for the three and nine months ended December 31, 2019 and 2018 (unaudited) 5
  Condensed Statement of Cash Flows for the nine months ended December 31, 2019 and 2018 (unaudited) 6
  Notes to Condensed Financial Statements (unaudited) 7
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 17
Item 3 Quantitative and Qualitative Disclosures About Market Risk 22
Item 4 Controls and Procedures 22
PART II OTHER INFORMATION  
Item 1. Legal Proceedings 23
Item 1A. Risk Factors 23
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
Item 3 Defaults Upon Senior Securities 23
Item 4 Mine Safety Disclosures 23
Item 5 Other Information 23
Item 6 Exhibits 23
  Signatures 24

 

2

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

Balance Sheets

(In thousands, except per share and per share amounts)

 

   December 31, 2019   March 31, 2019 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $447   $172 
Accounts receivable-trade, net of allowance of $5 as of December 31, 2019 and March 31, 2019   213    483 
Accounts receivable-other   343    185 
Assets held for sale   2,067    2,091 
Prepaid expenses and other current assets   113    3 
Total current assets   3,183    2,934 
Other assets   47    47 
Total assets  $3,230   $2,981 
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $497   $467 
Accrued expenses   446    342 
Customer advance   191    24 
Liabilities held for sale   2,490    2,536 
Related party notes payable   -    140 
Total current liabilities   3,624    3,509 
Total liabilities   3,624    3,509 
           
Commitments and contingencies (See Note 14)   -    - 
           
Stockholders’ deficit:          
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2019 and March 31, 2019   -    - 
Common stock; $.001 par value; 50,000,000 shares authorized; 28,339,063 shares issued; and 28,262,371 shares outstanding as of December 31, 2019 and March 31, 2019   28    21 
Additional paid-in capital   38,610    38,427 
Accumulated deficit   (39,002)   (38,946)
Treasury stock, 76,692 shares at cost as of December 31, 2019 and March 31, 2019   (30)   (30)
Total stockholders’ deficit   (394)   (528)
Total liabilities and stockholders’ deficit  $3,230   $2,981 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

Statements of Operations

(Unaudited – In thousands, except per share amounts)

 

   For the Three Months Ended December 31, 2019   For the Three Months Ended December 31, 2018   For the Nine Months Ended December 31, 2019   For the Nine Months Ended December 31, 2018 
                 
Operating expenses   (65)   (54)   (185)   (152)
Loss from continuing operations before provision for income taxes   (65)   (54)   (185)   (152)
Provision for income taxes   -    -    -    - 
Loss from continuing operations  $(65)  $(54)  $(185)  $(152)
Income (loss) from discontinued operations, net of income taxes   (86)   570    129    602 
Net income (loss)  $(151)  $516   $(56)  $450 
                     
Income per common share - basic:                    
Continuing operations  $(0.00)  $(0.01)  $(0.01)  $(0.01)
Discontinued operations   (0.00)   0.03    (0.01)   0.03 
Net income per share - basic  $(0.01)  $0.02   $(0.00)  $0.02 
                     
Income per common share - diluted:                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   (0.00)   0.03    (0.01)   0.03 
Net income per share - diluted  $(0.01)  $0.02   $(0.00)  $0.02 
                     
Shares used in computing net income per common share:                    
Basic   23,498    21,491    22,157    21,491 
Diluted   23,498    22,711    22,157    22,627 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

Statement of Stockholders’ Deficit

(Unaudited – In thousands)

 

   Preferred Stock   Common Stock   Additional Paid-in    Accumulated   Treasury   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Stock   Deficit 
Balance at March 31, 2018   -   $-    21,491   $21   $38,404   $(39,280)  $(30)  $(885)
Net loss                            (91)        (91)
Balance at June 30, 2018   -    -    21,491    21    38,404    (39,371)   (30)   (976)
Stock-based compensation                       19              19 
Net income                            25         25 
Balance at September 30, 2018   -    -    21,491    21    38,423    (39,346)   (30)   (932)
Net income                            516         516 
Balance at December 31, 2018   -   $-    21,491   $21   $38,423   $(38,830)  $(30)  $(416)
                                         
Balance at March 31, 2019   -   $-    21,491   $21   $38,427   $(38,946)  $(30)  $(528)
Net income                            83         83 
Balance at June 30, 2019   -    -    21,491    21    38,427    (38,863)   (30)   (445)
Net income                            12         12 
Balance at September 30, 2019   -    -    21,491    21    38,427    (38,851)   (30)   (433)
Common stock issued on exercise of stock options             5,941    6    159              165 
Common stock on exercise of warrants             830    1    24              25 
Net loss                            (151)        (151)
Balance at December 31, 2019   -   $-    28,262   $28   $38,610   $(39,002)  $(30)  $(394)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

Statements of Cash Flows

(Unaudited – In thousands)

 

   For the Nine Months Ended December 31, 
   2019   2018 
Cash flows from operating activities:          
Loss from continuing operations  $(185)  $(152)
Income from discontinued operations   129    602 
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:          
Stock-based compensation   -    19 
Changes in assets and liabilities:          
Accounts receivable-trade   270    (234)
Accounts receivable-other   (158)   127 
Prepaid expenses and other current assets   (110)   - 
Accounts payable   30    (9)
Accrued expenses   104    (28)
Customer advance   167    (40)
Net cash flows provided by (used in) operating activities of continuing operations   118    (317)
Net cash flows provided by operating activities of discontinued operations   107    295 
Net cash flows provided by (used in) operating activities   225    (22)
Cash flows from financing activities:          
Issuance of common stock   190    - 
Repayment of related party notes payable   (140)   (5)
Net cash flows provided by (used in) financing activities   50    (5)
Net change in cash   275    (27)
Cash at beginning of period   172    120 
Cash at end of period  $447   $93 
           
Supplemental disclosure of cash flow information:          
Income taxes paid  $-   $- 
Interest paid  $278   $280 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

6

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

1. Business Description

 

On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

 

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

 

Prior to the Closing Date, our corporate, development and manufacturing operations were located in a leased facility in Wilmington, Massachusetts.

 

2. Going Concern

 

Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2019, we recorded our normal business operations as discontinued operations as a result of the previously described Asset Sale. Within ninety (90) days of the Closing Date, the Board of Directors is expected to declare a distribution of the net proceeds from the Asset Sale, after making adjustments for (i) collection of accounts receivable retained as of January 31, 2020, (ii) payment of accounts payable assumed as of January 31, 2020; and (iii) retention of a reasonable amount of cash for anticipated future obligations. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, management believes there is substantial doubt about our ability to continue as a going concern.

 

Management is seeking to identify an operating company for the purpose of effecting a merger or business combination, or to acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements.

 

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target’s management to have proven its abilities or effectiveness, or the lack of an established market for the target’s products or services, or the inability to reach profitability in the next few years.

 

Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.

 

7

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

3. Interim Financial Statements and Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three and nine months ended December 31, 2019 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The information contained in this quarterly report on Form 10-Q should be read in conjunction with our audited financial statements included in our annual report on Form 10-K, as of and for the year ended March 31, 2019 as filed with the Securities and Exchange Commission (the “SEC”).

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments, which are evaluated on an ongoing basis, and that affect the amounts reported in our unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to revenue recognition, allowance for doubtful accounts, inventory reserves, useful lives and valuation of property and equipment.

 

Our significant accounting policies are described in Note 3 to the audited financial statements as of March 31, 2019 which are included in our Annual Report on Form 10-K as filed with the SEC on August 23, 2019.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. these reclassifications had no effect on the previously reported financial position or results of operations.

 

4. Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on our accounting and reporting. We believe that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on our accounting or reporting or that such impact will not be material to our financial position, results of operations and cash flows when implemented.

 

Recent accounting pronouncements are included in Note 3 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2019.

 

5. Held for Sale Assets and Liabilities and Discontinued Operations

 

On November 25, 2019, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the “Asset Sale”). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020 (the “Closing Date”), we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.

 

8

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

Pursuant to the Purchase Agreement, we sold all of our inventory; property, plant and equipment; and intangible assets, including but not limited to all intellectual property, business know-how, customer lists and related contracts, and all other assets necessary to operate our advanced polymer business. All cash; accounts receivable; prepaid expenses; deposits on facility lease; accounts payable; and accrued expenses as of the Closing Date were retained by us. We believe the Asset Sale meets the accounting criteria for held for sale assets, accordingly, the following presents the components of held for sale assets as of December 31, 2019:

 

Held for Sale Assets

 

Assets of Discontinued Operations Held for Sale  December 31, 2019   March 31, 2019 
(in thousands)          
Inventories, net  $ 271    $ 248  
Property, plant and equipment, net   1,749    1,791 
Deferred financing costs, net   47    52 
Assets of discontinued operations held for sale  $ 2,067    $ 2,091  

 

We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:

 

(in thousands)  December 31, 2019   March 31, 2019 
         
Raw materials  $129   $121 
Work in progress   35    48 
Finished goods   107    79 
Total inventories, net  $271   $248 

 

We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:

 

Property, plant and equipment which were included in held for sale assets consist of the following:

 

(in thousands)  December 31, 2019   March 31, 2019 
         
Land  $500   $500 
Building   2,705    2,705 
Machinery, equipment and tooling   1,248    1,248 
Furniture, fixtures and office equipment   285    285 
Office equipment under capital lease   13    13 
    4,752    4,751 
Less: accumulated depreciation   (3,003)   (2,960)
Property, plant and equipment, net  $1,749   $1,791 

 

Our lease with the independent third-party owner of the land and building was assigned to MCPP at which time all of our obligations with respect to the lease agreement were relieved.

 

Held for Sale Liabilities

 

On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. For accounting purposes, this sale-leaseback transaction was accounted for under the financing method, rather than as a completed sale. Under the financing method, we included the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (“MCPP”), which was completed on January 31, 2020, our lease with the independent third-party owner of the building was assigned to MCPP. As a result, we recorded the aggregate financing obligation and accrued interest on financing obligation of approximately $2,141,000 and $2,154,000 was recorded as liabilities held for sale in our balance sheet. Subsequent to the January 31, 2020, we had no further obligations with respect to the lease agreement.

 

9

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

Discontinued Operations

 

As a result of the Asset Sale, we discontinued operating as a developer, manufacturer, marketer and seller of advanced polymers on the Closing Date. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. Accordingly, the results of our operations are reported as discontinued operations for all periods are presented below.

 

Results of Discontinued Operations  For the Three Months Ended December 31, 2019   For the Three Months Ended December 31, 2018   For the Nine Months Ended December 31, 2019   For the Nine Months Ended December 31, 2018 
(in thousands)                    
Revenues:                    
Product sales  $457   $608   $1,632   $1,564 
License and royalty fees   351    281    803    708 
Total revenues   808    889    2,435    2,272 
Cost of sales   194    259    641    670 
Gross profit   614    630    1,794    1,602 
Operating expenses:                    
Research, development and regulatory   103    77    280    253 
Selling, general and administrative   495    271    1,049    847 
Total operating expenses   598    348    1,329    1,100 
Income (loss) from discontinued operations   16    282    465    502 
Other income (expense) from discontinued operations, net:                    
Gain on disposition of sales-leaseback assets   34    382    34    382 
Interest expense   (136)   (94)   (370)   (282)
Other income (expense) from discontinued operations, net   (102)   288    (336)   100 
Income (loss) from discontinued operations before provision for income taxes   (86)   570    129    602 
Provision for income taxes   -    -    -    - 
Net income (loss) from discontinued operations  $(86)  $570   $129   $602 
                     
Net income (loss) from discontinued operations per common share:                    
Basic  $(0.00)  $0.03   $0.01   $0.03 
Diluted   (0.00)   0.03    0.01    0.03 
                     
Shares used in computing net income from discontinued operations per common share:                    
Basic   23,498    21,491    22,157    21,491 
Diluted   23,498    22,711    22,157    22,627 

 

10

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

Continuing Operations

 

Our loss from continuing operations represents those costs necessary to operate a public company in the approximate amount of $65,000 and $185,000 during the three and nine months ended December 31, 2019, respectively; and $54,000 and $152,000 during the three and nine months ended December 31, 2018, respectively. These costs were composed of accounting fees, professional fees, regulatory fees, board of directors fees, and director and officer liability insurance premiums.

 

6. Related Party Transactions

 

On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the “Carroll Note”). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.

 

On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the “Affiliate”) in the principal amount of $25,000 (the “First Affiliate Note”). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.

 

On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the “Second Affiliate Note”). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.

 

As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the “Affiliate Notes”) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the “2017 Option Plan”). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.

 

During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.

 

7. Income Per Share

 

Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per common share are based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted income per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 410,000 shares and 410,000 shares for the three and nine months ended December 31, 2019. Potentially dilutive shares, which were included in the diluted income per share calculations for the three and nine months ended December 31, 2018 were 1,220,008 shares and 1,137,025 shares.

 

11

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

8. Income Taxes

 

We are required to file federal and state income tax returns in the United States. The preparation of these tax returns requires us to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by us. In consultation with our tax advisors, we base our tax returns on interpretations that are believed to be reasonable under the circumstances. The tax returns, however, are subject to routine reviews by the various federal and state taxing authorities in the jurisdictions in which we file tax returns. As part of these reviews, a taxing authority may disagree with respect to the income tax positions taken by us (“uncertain tax positions”) and, therefore, may require us to pay additional taxes. As required under applicable accounting rules, we accrue an amount for our estimate of additional income tax liability, including interest and penalties, which we could incur as a result of the ultimate or effective resolution of the uncertain tax positions. We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

We had no income tax credits for the three and nine months ended December 31, 2019 and 2018. The effective tax rates for the three and nine months ended December 31, 2019 was 21.0%. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.

 

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.

 

9. Promissory Notes

 

On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the “Carroll Note”). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.

 

12

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the “Affiliate”) in the principal amount of $25,000 (the “First Affiliate Note”). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.

 

On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the “Second Affiliate Note”). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.

 

As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the “Affiliate Notes”) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the “2017 Option Plan”). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.

 

During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.

 

10. Long-Term Financing Obligation

 

On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. In addition, we provided, as collateral, a security interest in all furnishings, fixtures and equipment owned and used by us, having a net book value of approximately $0 as of December 31, 2019. For accounting purposes, the provision of such collateral constitutes continuing involvement with the associated property. Due to this continuing involvement, this sale-leaseback transaction is accounted for under the financing method, rather than as a completed sale. Under the financing method, we include the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. Through December 2018, interest on the financing obligation exceeded the minimum lease payments, accordingly the principal remains constant through that date. After December 2018, the minimum lease payment will exceed interest and principal will be reduced by the excess of minimum lease payment over interest. The building, building improvements and land remain on the condensed balance sheet and the building and building improvements will continue to be depreciated over their remaining useful lives. Payments made under the lease are applied as payments of imputed interest and deemed principal on the underlying financing obligation.

 

In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (“MCPP”), which was completed on January 31, 2020 (the “Closing Date”), our lease with the independent third-party owner of the building was assigned to MCPP. As a result, subsequent to the Closing Date, we have no further obligations with respect to the lease agreement.

 

13

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

11. Stockholders’ Deficit

 

Common Stock Warrants

 

On July 22, 2015, we engaged the services of a financial and strategic advisor (the “Advisor”) whose services include, but are not limited to, financial advice, strategic advice and investment banking services. In connection with this engagement, we agreed to compensate the Advisor approximately $4,000 per quarter for a one-year period and we issued them a warrant to purchase 830,500 shares of our common stock at an exercise price of $0.03 per share, the approximate fair value of our common stock on the date of the engagement. The warrant is exercisable at any time until July 21, 2025. The warrant was valued at approximately $28,000 using the Black-Scholes model and treated as permanent equity.

 

On November 27, 2019, the Advisor exercised the warrant to purchase 830,500 shares of our common stock in consideration of approximately $25,000 in cash.

 

Common Stock Options

 

On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Stock Option Plan. In consideration for the exercise of these options we received approximately $40,000 in cash.

 

On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the “Adams Option”) at an exercise price of $0.06 per share pursuant to the 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”). On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the “Grantees”) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

12. Stock-Based Compensation

 

In October 2003, our shareholders approved the AdvanSource 2003 Stock Option Plan (the “2003 Plan”), which authorizes the issuance of 3,000,000 shares of common stock. Under the terms of the Plan, the exercise price of Incentive Stock Options issued under the Plan must be equal to the fair market value of the common stock at the date of grant. In the event that Non-Qualified Options are granted under the Plan, the exercise price may be less than the fair market value of the common stock at the time of the grant (but not less than par value). Total shares of common stock registered under the 2003 Plan are 7,000,000 shares. Normally, options granted expire ten years from the grant date.

 

14

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

Activity under the 2003 Plan for the nine months ended December 31, 2019 is as follows:

 

   Number of Options   Weighted-Average Exercise Price per Share   Weighted-
Average Remaining Contractual
Term in Years		   Aggregate Intrinsic Value (in thousands) 
Options outstanding as of April 1, 2019   1,788,750   $0.20    2.03   $20 
Granted   -                                      
Exercised   (656,250)               
Cancelled or forfeited   (722,500)  $0.29           
Options outstanding as of December 31, 2019   410,000   $0.27    0.23   $1 
Options exercisable as of December 31, 2019   410,000   $0.27    0.23   $1 
Options vested or expected to vest as of December 31, 2019   410,000   $0.27    0.23   $1 

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on December 31, 2019 of $0.165 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on December 31, 2019.

 

On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Plan. In consideration for the exercise of these options we received approximately $40,000 in cash. There were no stock options exercised under the 2003 Plan for the three and nine months ended December 31, 2018. As of December 31, 2019, there were no shares remaining to be granted under the 2003 Plan.

 

For the three and nine months ended December 31, 2019 and 2018, we recorded no stock-based compensation expense for options pursuant to the 2003 Plan. As of December 31, 2019, we had no unrecognized compensation cost related to stock options.

 

On August 14, 2017, our board of directors approved and adopted the 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”), which authorized the grant of non-qualified stock options exercisable into a maximum of 7,000,000 shares of our common stock. Under the terms of the 2017 Plan, the exercise price of stock options issued under the 2017 Plan must be equal to the fair market value of the common stock at the date of grant. Options granted expire ten years from the grant date. From August 17, 2017 through December 13, 2018, the board of directors approved the grant of stock options to certain directors, employees and a consultant which were immediately vested and exercisable into a total of 6,550,000 shares of our common stock. There were no additional stock options granted pursuant to the 2017 Plan for the period subsequent to December 31, 2018. In determining the fair value of the options granted pursuant to the 2017 Plan, we utilized the Black-Scholes pricing model utilizing the following assumptions:

 

   August 17, 2017 Option Grants   August 16, 2018 Option Grants   December 13, 2018 Option Grants 
Total shares granted   5,600,000    750,000    200,000 
Option exercise price per share  $0.06   $0.040   $0.060 
Grant date fair market value per share  $0.06   $0.046   $0.059 
Expected term of option in years   10.0    2.00    1.00 
Expected volatility   100%   100%   100%
Expected dividend rate   0.00%   0.00%   0.00%
Risk free interest rate   1.00%   0.00%   2.69%

 

On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the “Adams Option”) at an exercise price of $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

15

 

 

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2019

(UNAUDITED)

 

On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the “Grantees”) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

As of December 31, 2019, there were 450,000 shares available to grant pursuant to the 2017 Plan and no options outstanding or exercisable.

 

13. Concentrations of Credit Risk and Major Customers

 

For the three months ended December 31, 2019 and 2018, two customers represented approximately 49% of our total revenues from discontinued operations and three customers represented approximately 66% of our total revenues, respectively.

 

For the nine months ended December 31, 2019 and 2018, three customers represented approximately 52% of our total revenues from discontinued operations and three customers represented approximately 53% of our total revenues, respectively.

 

As of December 31, 2019, we had accounts receivable-trade of approximately $100,000, or 47%, due from two customers. As of March 31, 2019, we had accounts receivable-trade of approximately $61,000, or 13%, due from one customer.

 

As of December 31, 2019 and March 31, 2019, we had approximately $343,000 due from two customers and $185,000 due from two customers, respectively, related to receivables on license fees and royalties. These amounts are classified as accounts receivable-other in our balance sheets.

 

14. Legal Proceedings

 

We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.

 

15. Subsequent Events

 

We evaluated all events or transactions that occurred after the balance sheet date through the date when we filed these financial statements and, other than as discussed below, we determined that we did not have any other material recognizable subsequent events.

 

On November 25, 2019, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the “Asset Sale”). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020, we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.

 

16

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward-Looking Statements

 

This quarterly report on Form 10-Q contains certain statements that are “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Litigation Reform Act”). These forward looking statements and other information are based on our beliefs as well as assumptions made by us using information currently available.

 

The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “will,” “should” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or using other similar expressions.

 

In accordance with the provisions of the Litigation Reform Act, we are making investors aware that such forward-looking statements, because they relate to future events, are by their very nature subject to many important factors that could cause actual results to differ materially from those contemplated by the forward-looking statements contained in this quarterly report on Form 10-Q. For example, we may encounter competitive, technological, financial and business challenges making it more difficult than expected to continue to develop and market our products; the market may not accept our existing and future products; we may not be able to retain our customers; we may be unable to retain existing key management personnel; and there may be other material adverse changes in our operations or business. Certain important factors affecting the forward-looking statements made herein also include, but are not limited to (i) continued downward pricing pressures in our targeted markets, (ii) the continued acquisition of our customers by certain of our competitors, and (iii) continued periods of net losses, which could require us to find additional sources of financing to fund operations, implement our financial and business strategies, meet anticipated capital expenditures and fund research and development costs. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause us to alter our marketing, capital expenditure or other budgets, which may in turn affect our financial position and results of operations. For all of these reasons, the reader is cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date hereof. We assume no responsibility to update any forward-looking statements as a result of new information, future events, or otherwise except as required by law. For further information, you are encouraged to review our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 and the risk factors discussed therein under Part I. Item 1A.

 

Business

 

On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

 

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

 

Management is seeking to identify an operating company and engage in a merger or business combination of some kind, or acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements.

 

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target’s management to have proven its abilities or effectiveness, or the lack of an established market for the target’s products or services, or the inability to reach profitability in the next few years.

 

17

 

 

Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.

 

Critical Accounting Policies

 

Our critical accounting policies are summarized in Note 3 to our consolidated financial statements included in Item 8 of our annual report on Form 10-K for the fiscal year ended March 31, 2019. However, certain of our accounting policies require the application of significant judgment by our management, and such judgments are reflected in the amounts reported in our financial statements. In applying these policies, our management uses its judgment to determine the appropriate assumptions to be used in the determination of estimates. Those estimates are based on our historical experience, terms of existing contracts, our observance of market trends, information provided by our strategic partners and information available from other outside sources, as appropriate. Actual results may differ significantly from the estimates contained in our unaudited condensed financial statements. There have been no changes to our critical accounting policies during the fiscal quarter ended December 31, 2019.

 

Results of Operations

 

As a result of the Asset Sale described above, which closed on January 31, 2020, our sole business operations of developing, manufacturing, marketing and selling of advanced polymers ceased. Accordingly, we have recorded all operations for the three- and nine-month period ended December 31, 2019 as discontinued operations. The following separately presents our results of continuing operations, which are composed of costs necessary to operate as a public company; and results of our discontinued operations, composed revenue and costs of operating the advanced polymer business.

 

Results of Continuing Operations

 

Our loss from continuing operations represents those costs necessary to operate a public company. During the three months ended December 31, 2019 and 2018, these costs were approximately $65,000 and $54,000, respectively, an increase of $11,000 or 20.3%. During the nine months ended December 31, 2019 and 2018, these costs were approximately $185,000 and $152,000, respectively, an increase of $33,000 or 21.7%. These costs were composed of accounting fees, professional fees, regulatory fees, board of directors fees, and director and officer liability insurance premiums.

 

Results of Discontinued Operations

 

For the Three Months Ended December 31, 2019 vs December 31, 2018

 

Revenues

 

Total revenues from discontinued operations for the three months ended December 31, 2019 were approximately $808,000 as compared with approximately $889,000 for the prior year period, a decrease of approximately $81,000, or 9.1%.

 

Product sales from discontinued operations for the three months ended December 31, 2019 were approximately $457,000 as compared with approximately $608,000 for the prior year period, a decrease of approximately $151,000, or 24.8%. The decrease is due to reductions in product shipments to certain key customers.

 

License and royalty fees from discontinued operations for the three months ended December 31, 2019 were approximately $351,000 as compared with approximately $281,000 for the prior year period, an increase of approximately $70,000 or 24.9%. License and royalty fees increased primarily as a result of minimum royalties earned at calendar year-end pursuant to an arrangement with one of two customers with whom we have royalty arrangements.

 

Gross Profit

 

Gross profit on total revenues from discontinued operations for the three months ended December 31, 2019 was approximately $614,000, or 76.0% of total revenues, compared with approximately $630,000, or 70.9% of total revenues, for the prior year period. Gross profit dollars for the three months ended December 31, 2019 decreased as compared to the prior year period as a result of decreased product sales. Gross profit as a percentage of total revenues for the three months ended December 31, 2019 as compared to the prior year period increased primarily due to increased fees from royalties.

 

18

 

 

Gross profit on product sales from discontinued operations for the three months ended December 31, 2019 was approximately $263,000, or 57.6% of product sales, compared with approximately $349,000, or 57.4% of product sales, for the prior year period. Although gross profit as a percentage of product sales remained fairly stable for the three months ended December 31, 2019, gross profit dollars decreased primarily due to decreased product sales in the three months ended December 31, 2019 as compared to the comparable prior year period.

 

Research, Development and Regulatory Expenses

 

Research and development expenses of discontinued operations for the three months ended December 31, 2019 were approximately $103,000 as compared with approximately $77,000 for the prior year period, an increase of approximately $26,000, or 33.8%. Research and development expense increased primarily as a result of increases in payroll costs and outside services.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses of discontinued operations for the three months ended December 31, 2019 were approximately $495,000 as compared with approximately $271,000 for the prior year period, an increase of approximately $224,000, or 82.7%. Selling, general and administrative expenses primarily increased as a result of increases in payroll costs in the sales and marketing department, executive management bonus, and outside consulting services.

 

Gain on Disposition of Sale-Leaseback Assets

 

Gain on disposition of sale-leaseback assets for the three months ended December 31, 2019 was approximately $34,000 as compared to approximately $348,000 for the comparable prior year period, a decrease of approximately $314,000. The decrease is primarily a result of recording the affect of the gain on the disposition of sale-leaseback assets in the prior year period.

 

Interest Expense

 

Interest expense of continuing operations for the three months ended December 31, 2019 was approximately $136,000 as compared to approximately $94,000 for the comparable prior year period, an increase of $42,000 or 44.7%. Interest expense is composed primarily of (i) interest accrued in connection with the financing obligation of approximately $87,000 and $88,000 for the three months ended December 31, 2019 and 2018, respectively; and (ii) accrual of interest of approximately $32,000 on facility lease obligations for the three months ended December 31, 2019.

 

For the Nine Months Ended December 31, 2019 vs December 31, 2018

 

Revenues

 

Total revenues from discontinued operations for the nine months ended December 31, 2019 were approximately $2,435,000 as compared with approximately $2,272,000 for the prior year period, an increase of approximately $163,000, or 7.2%.

 

Product sales from discontinued operations for the nine months ended December 31, 2019 were approximately $1,632,000 as compared with approximately $1,564,000 for the prior year period, an increase of approximately $68,000, or 4.4%. The slight increase is due to greater product shipments to certain key customers during the two fiscal quarters ended September 30, 2019 which offset the reduced product shipments during the fiscal quarter ended December 31, 2019.

 

License and royalty fees from discontinued operations for the nine months ended December 31, 2019 were approximately $803,000 as compared with approximately $708,000 for the prior year period, an increase of approximately $95,000 or 13.4%. License and royalty fees increased primarily as a result of minimum royalties earned at calendar year-end pursuant to an arrangement with one of two customers with whom we have royalty arrangements.

 

Gross Profit

 

Gross profit on total revenues from discontinued operations for the nine months ended December 31, 2019 was approximately $1,794,000, or 73.7% of total revenues, compared with approximately $1,602,000, or 70.5% of total revenues, for the prior year period. Gross profit dollars and gross profit as a percentage of total revenues for the nine months ended December 31, 2019 increased as compared to the prior year period as a result of slight increases in both product sales and royalties.

 

19

 

 

Gross profit on product sales from discontinued operations for the nine months ended December 31, 2019 was approximately $991,000, or 60.7% of product sales, compared with approximately $894,000, or 57.2% of product sales, for the prior year period. Gross profit dollars and gross profit as a percentage of total revenues for the nine months ended December 31, 2019 increased as compared to the prior year period as a result of the increase in product sales.

 

Research, Development and Regulatory Expenses

 

Research and development expenses of discontinued operations for the nine months ended December 31, 2019 were approximately $280,000 as compared with approximately $253,000 for the prior year period, an increase of approximately $27,000, or 10.7%. Research and development expense increased primarily as a result of increases in payroll costs and outside services.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses of discontinued operations for the nine months ended December 31, 2019 were approximately $1,049,000 as compared with approximately $847,000 for the prior year period, an increase of approximately $202,000, or 23.9%. Selling, general and administrative expenses primarily increased as a result of increases in payroll costs in the sales and marketing department, executive management bonus, and outside consulting services.

 

Gain on Disposition of Sale-Leaseback Assets

 

Gain on disposition of sale-leaseback assets for the three months ended December 31, 2019 was approximately $34,000 as compared to approximately $382,000 for the comparable prior year period, a decrease of approximately $314,000. The decrease is primarily a result of recording the affect of the gain on the disposition of sale-leaseback assets in the prior year period.

 

Interest Expense

 

Interest expense of continuing operations for the nine months ended December 31, 2019 was approximately $370,000 as compared to approximately $282,000 for the comparable prior year period, an increase of $88,000 or 31.2%. Interest expense is composed primarily of (i) interest accrued in connection with the financing obligation of approximately $262,000 and $263,000 for the nine months ended December 31, 2019 and 2018, respectively; (ii) accrual of interest of approximately $32,000 on facility lease obligations for the nine months ended December 31, 2019; and (iii) accrual of interest of approximately $46,000 on local regulatory obligations for the nine months ended December 31, 2019.

 

Liquidity and Capital Resources

 

As of December 31, 2019, we had cash of approximately $447,000 as compared to a cash balance of approximately $172,000 as of March 31, 2019.

 

During the nine months ended December 31, 2019, we had net cash of approximately $225,000 provided by operating activities as compared with net cash of approximately $22,000 used in operating activities for the prior year period. Our cash flows provided by operating activities of continuing operations in the approximate amount of $118,000 for the nine months ended December 31, 2019 consisted primarily of (i) collections of accounts receivable-trade of approximately $270,000; (ii) increases in aggregate accounts payable and accrued expenses of approximately $134,000; and (iii) increase in customer advances of approximately $167,000 of which approximately $191,000 represented and advance from one customer for future shipments. These cash flows provided by operating activities of continuing operations were primarily offset by (i) our loss from continuing operations of $185,000; (ii) increases of accounts receivables on royalty arrangements of approximately $100,000; and (iii) increases of prepaid expenses for professional fees related to the sale of asset transaction. Our cash flows used in operating activities of continuing operations in the approximate amount of $317,000 for the nine months ended December 31, 2018 consisted primarily of (i) our loss from continuing operations of approximately $152,000; (ii) increases in accounts receivable-trade of approximately $234,000; and (iii) decreases in aggregate accounts payable, accrued expenses and customer advances of approximately $77,000. These cash flows used in operating activities of continuing operations were primarily offset by increases of collections on accounts receivables on royalty arrangements of approximately $127,000.

 

Our cash flows provided by operating activities of discontinued operations in the approximate amount of $107,000 for the nine months ended December 31, 2019 consisted primarily of income from discontinued operations of approximately $129,000 offset by the additional net gain on disposition of sale-leaseback asset and extinguishment of long-term financing obligation of approximately $34,000. Our cash flows provided by operating activities of discontinued operations in the approximate amount of $295,000 for the nine months ended December 31, 2018 consisted primarily of income from discontinued operations of approximately $602,000 offset by the net gain on disposition of sale-leaseback asset and extinguishment of long-term financing obligation of approximately $382,000.

 

20

 

 

During the nine months ended December 31, 2019, we provided cash of $50,000 for financing activities. We issued 830,500 shares and 656,250 shares of our common stock pursuant to the exercise of common stock purchase warrants and incentive stock options, respectively, which were purchased for cash in the approximate aggregate amount of $65,000. We also repaid two notes payable to an affiliate of our chief executive officer, in the aggregate principal amount of $125,000. In lieu of a cash payment for the repayment of these notes, the affiliate allowed our chief executive officer to exercise a portion of his non-qualified stock options to purchase 2,083,333 shares of our common stock. We issued an additional 3,201,667 shares of our common stock pursuant to the cashless exercise of non-qualified stock options granted to our directors, employees and a consultant.

 

On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

 

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

 

Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2019, we recorded our normal business operations as discontinued operations as a result of the previously described Asset Sale. On the Closing Date we received net proceeds from the Asset Sale of approximately $6,100,000. Within ninety (90) days of the Closing Date, the Board of Directors is expected to declare a distribution of the net proceeds from the Asset Sale, after making adjustments for (i) collection of accounts receivable retained as of January 31, 2020, (ii) payment of accounts payable assumed as of January 31, 2020; and (iii) retention of a reasonable amount of cash for anticipated future obligations. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, management believes there is substantial doubt about our ability to continue as a going concern.

 

Management is seeking to identify an operating company for the purpose of effecting a merger or business combination, or to acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements.

 

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target’s management to have proven its abilities or effectiveness, or the lack of an established market for the target’s products or services, or the inability to reach profitability in the next few years.

 

Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.

 

21

 

 

Commitments

 

We do not have any long-term commitments at December 31, 2019.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2019, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

The certificates of our principal executive officer and principal financial and accounting officer attached as Exhibits 31.1 and 31.2 to this Quarterly Report on Form 10-Q include, in paragraph 4 of such certifications, information concerning our disclosure controls and procedures, and internal control over financial reporting. Such certifications should be read in conjunction with the information contained in this Item 4 for a more complete understanding of the matters covered by such certifications.

 

Disclosure Controls and Procedures

 

Our management, with the participation of our chief executive officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer concluded that our disclosure controls and procedures as of December 31, 2019 were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. We intend to take appropriate and reasonable steps to make improvements to remediate these deficiencies.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes to the Company’s internal control over financial reporting during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

22

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.

 

Item 1A. Risk Factors

 

Not applicable.

 

Item 2. Unregistered Sales of Equity Securities

 

On November 27, 2019, we issued 830,500 shares of our common stock to an advisor upon the exercise of common stock purchase warrant that was granted to the advisor on July 22, 2015.

 

On December 5, 2019, we issued to our directors and certain employees a total of 656,250 shares of our common stock upon the exercise of incentive and non-qualified stock options granted pursuant to the terms of our 2003 Stock Option Plan.

 

On December 5, 2019, we issued to our directors, certain employees and one consultant a total of 5,285,000 shares of our common stock upon the exercise of non-qualified stock options granted pursuant to the terms of our 2017 Non-Qualified Equity Incentive Plan.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit No.   Description
31.1   Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of the Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1   Certification of the Chief Executive Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   XBRL Instance Document.
101.SCH   XBRL Taxonomy Extension Schema Document.
101.CAL   XBRL Taxomony Extension Calculation Linkbase Document.
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.

 

23

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ADVANSOURCE BIOMATERIALS CORPORATION
   
  By: /s/ Michael F. Adams
    Michael F. Adams
   

Chief Executive Officer and President

    (Principal Executive, Financial and Accounting Officer)
     
Dated: April 1, 2020    

 

24

 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Michael F. Adams, hereby certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of AdvanSource Biomaterials Corporation (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: April 1, 2020  
   
/s/ Michael F. Adams  
Michael F. Adams  
Chairman, Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Michael F. Adams, hereby certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of AdvanSource Biomaterials Corporation (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: April 1, 2020  
   
/s/ Michael F. Adams  
Michael F. Adams  
Chairman, Chief Executive Officer  
(Principal Financial and Accounting Officer)  

 

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of AdvanSource Biomaterials Corporation, a Delaware corporation (the “Company”), on Form 10-Q for the fiscal quarter ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael F. Adams, Chief Executive Officer and President of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 1, 2020  
   
/s/ Michael F. Adams  
Michael F. Adams  
Chief Executive Officer and President  

 

This certification accompanies each report of the Company on Form 10-Q and Form 10-K pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

 EX-101.INS 5 asnb-20191231.xml XBRL INSTANCE FILE 0001011060 2019-04-01 2019-12-31 0001011060 2020-04-01 0001011060 2019-12-31 0001011060 2019-03-31 0001011060 2018-04-01 2018-12-31 0001011060 2018-10-01 2018-12-31 0001011060 2019-10-01 2019-12-31 0001011060 2018-04-01 2018-06-30 0001011060 2018-07-01 2018-09-30 0001011060 2019-04-01 2019-06-30 0001011060 2019-07-01 2019-09-30 0001011060 2018-03-31 0001011060 2018-06-30 0001011060 2018-09-30 0001011060 2018-12-31 0001011060 2019-06-30 0001011060 2019-09-30 0001011060 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0001011060 us-gaap:PreferredStockMember 2018-03-31 0001011060 us-gaap:PreferredStockMember 2018-06-30 0001011060 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001011060 us-gaap:CommonStockMember 2018-03-31 0001011060 us-gaap:CommonStockMember 2018-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001011060 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001011060 us-gaap:RetainedEarningsMember 2018-03-31 0001011060 us-gaap:RetainedEarningsMember 2018-06-30 0001011060 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001011060 us-gaap:TreasuryStockMember 2018-03-31 0001011060 us-gaap:TreasuryStockMember 2018-06-30 0001011060 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001011060 us-gaap:PreferredStockMember 2018-09-30 0001011060 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001011060 us-gaap:CommonStockMember 2018-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001011060 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001011060 us-gaap:RetainedEarningsMember 2018-09-30 0001011060 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001011060 us-gaap:TreasuryStockMember 2018-09-30 0001011060 us-gaap:PreferredStockMember 2018-10-01 2018-12-31 0001011060 us-gaap:PreferredStockMember 2018-12-31 0001011060 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001011060 us-gaap:CommonStockMember 2018-12-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001011060 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001011060 us-gaap:RetainedEarningsMember 2018-12-31 0001011060 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0001011060 us-gaap:TreasuryStockMember 2018-12-31 0001011060 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001011060 us-gaap:PreferredStockMember 2019-03-31 0001011060 us-gaap:PreferredStockMember 2019-06-30 0001011060 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001011060 us-gaap:CommonStockMember 2019-03-31 0001011060 us-gaap:CommonStockMember 2019-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001011060 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001011060 us-gaap:RetainedEarningsMember 2019-03-31 0001011060 us-gaap:RetainedEarningsMember 2019-06-30 0001011060 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001011060 us-gaap:TreasuryStockMember 2019-03-31 0001011060 us-gaap:TreasuryStockMember 2019-06-30 0001011060 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001011060 us-gaap:PreferredStockMember 2019-09-30 0001011060 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001011060 us-gaap:CommonStockMember 2019-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001011060 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001011060 us-gaap:RetainedEarningsMember 2019-09-30 0001011060 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001011060 us-gaap:TreasuryStockMember 2019-09-30 0001011060 us-gaap:PreferredStockMember 2019-10-01 2019-12-31 0001011060 us-gaap:PreferredStockMember 2019-12-31 0001011060 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001011060 us-gaap:CommonStockMember 2019-12-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001011060 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001011060 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001011060 us-gaap:RetainedEarningsMember 2019-12-31 0001011060 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0001011060 us-gaap:TreasuryStockMember 2019-12-31 0001011060 us-gaap:SubsequentEventMember ASNB:AssetPurchaseAgreementMember 2020-01-30 2020-01-31 0001011060 ASNB:AssetPurchaseAgreementMember ASNB:MitsubishiChemicalPerformancePolymersIncMember 2019-11-24 2019-11-25 0001011060 us-gaap:SubsequentEventMember ASNB:AssetPurchaseAgreementMember ASNB:MitsubishiChemicalPerformancePolymersIncMember 2020-01-30 2020-01-31 0001011060 us-gaap:SubsequentEventMember ASNB:AssetPurchaseAgreementMember ASNB:MitsubishiChemicalPerformancePolymersIncMember 2020-01-31 0001011060 ASNB:AssetPurchaseAgreementMember ASNB:IndependentThirdPartyMember 2011-12-20 2011-12-22 0001011060 ASNB:AssetPurchaseAgreementMember ASNB:IndependentThirdPartyMember 2011-12-22 0001011060 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2019-12-31 0001011060 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2019-03-31 0001011060 ASNB:WorkInProgressMember 2019-12-31 0001011060 ASNB:WorkInProgressMember 2019-03-31 0001011060 ASNB:FinishedGoodsMember 2019-12-31 0001011060 ASNB:FinishedGoodsMember 2019-03-31 0001011060 us-gaap:LandMember 2019-12-31 0001011060 us-gaap:LandMember 2019-03-31 0001011060 us-gaap:BuildingMember 2019-12-31 0001011060 us-gaap:BuildingMember 2019-03-31 0001011060 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001011060 us-gaap:MachineryAndEquipmentMember 2019-03-31 0001011060 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001011060 us-gaap:FurnitureAndFixturesMember 2019-03-31 0001011060 ASNB:OfficeEquipmentUnderCapitalLeaseMember 2019-12-31 0001011060 ASNB:OfficeEquipmentUnderCapitalLeaseMember 2019-03-31 0001011060 ASNB:ProductSalesMember 2019-10-01 2019-12-31 0001011060 ASNB:ProductSalesMember 2018-10-01 2018-12-31 0001011060 ASNB:LicenseAndRoyaltyFeesMember 2019-10-01 2019-12-31 0001011060 ASNB:LicenseAndRoyaltyFeesMember 2018-10-01 2018-12-31 0001011060 ASNB:ProductSalesMember 2019-04-01 2019-12-31 0001011060 ASNB:ProductSalesMember 2018-04-01 2018-12-31 0001011060 ASNB:LicenseAndRoyaltyFeesMember 2019-04-01 2019-12-31 0001011060 ASNB:LicenseAndRoyaltyFeesMember 2018-04-01 2018-12-31 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2016-04-25 2016-04-26 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2016-04-26 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2019-04-01 2019-12-31 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2018-04-01 2018-12-31 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2018-10-01 2018-12-31 0001011060 ASNB:KhristineCarrollMember ASNB:CarrollNoteMember 2019-03-31 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2016-04-25 2016-04-26 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2016-04-26 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2018-10-01 2018-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2018-04-01 2018-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2019-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:FirstAffiliateNoteMember 2019-03-31 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2016-12-04 2016-12-05 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2016-12-05 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2018-10-01 2018-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2018-04-01 2018-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2019-12-31 0001011060 ASNB:MichaelAdamsMember ASNB:SecondAffiliateNoteMember 2019-03-31 0001011060 ASNB:AffiliateNotesMember ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember 2019-12-04 2019-12-05 0001011060 ASNB:AffiliateNotesMember ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember 2019-12-05 0001011060 ASNB:CarrollNoteMember 2019-10-01 2019-12-31 0001011060 ASNB:CarrollNoteMember 2018-10-01 2018-12-31 0001011060 ASNB:CarrollNoteMember 2019-04-01 2019-12-31 0001011060 ASNB:CarrollNoteMember 2018-04-01 2018-12-31 0001011060 ASNB:AffiliateNotesMember 2019-10-01 2019-12-31 0001011060 ASNB:AffiliateNotesMember 2018-10-01 2018-12-31 0001011060 ASNB:AffiliateNotesMember 2019-04-01 2019-12-31 0001011060 ASNB:AffiliateNotesMember 2018-04-01 2018-12-31 0001011060 2011-12-21 2011-12-22 0001011060 ASNB:CommonStockWarrantsMember ASNB:AdvisorMember 2015-07-21 2015-07-22 0001011060 ASNB:CommonStockWarrantsMember ASNB:AdvisorMember 2015-07-22 0001011060 ASNB:CommonStockWarrantsMember ASNB:AdvisorMember 2019-11-27 0001011060 ASNB:CommonStockOptionsMember ASNB:TwoThousandThreeStockOptionPlanMember ASNB:DirectorsAndCertainEmployeesMember 2019-12-04 2019-12-05 0001011060 ASNB:CommonStockOptionsMember ASNB:TwoThousandThreeStockOptionPlanMember ASNB:DirectorsAndCertainEmployeesMember 2019-12-05 0001011060 ASNB:CommonStockOptionsMember ASNB:MichaelAdamsMember ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember 2017-08-16 2017-08-17 0001011060 ASNB:CommonStockOptionsMember ASNB:MichaelAdamsMember 2019-12-04 2019-12-05 0001011060 ASNB:CommonStockOptionsMember ASNB:MichaelAdamsMember 2019-12-05 0001011060 ASNB:CommonStockOptionsMember ASNB:DirectorsCertainEmployeesAndOneConsultantMember srt:MinimumMember 2017-08-16 2018-12-13 0001011060 ASNB:CommonStockOptionsMember ASNB:DirectorsCertainEmployeesAndOneConsultantMember srt:MaximumMember 2017-08-16 2018-12-13 0001011060 ASNB:CommonStockOptionsMember 2019-12-04 2019-12-05 0001011060 ASNB:TwoThousandThreeStockOptionPlanMember 2003-10-31 0001011060 ASNB:TwoThousandThreeStockOptionPlanMember 2003-01-01 2003-10-31 0001011060 ASNB:CommonStockOptionsMember 2019-04-01 2019-12-31 0001011060 ASNB:CommonStockOptionsMember 2018-04-01 2018-12-31 0001011060 ASNB:CommonStockOptionsMember 2018-10-01 2018-12-31 0001011060 ASNB:TwoThousandThreeStockOptionPlanMember 2019-04-01 2019-12-31 0001011060 ASNB:TwoThousandThreeStockOptionPlanMember 2018-04-01 2018-12-31 0001011060 ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember ASNB:BoardOfDirectorsMember srt:MaximumMember 2017-08-13 2017-08-14 0001011060 ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember ASNB:BoardOfDirectorsMember 2017-08-13 2017-08-14 0001011060 ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember ASNB:DirectorsCertainEmployeesAndAConsultantMember 2017-08-16 2018-12-13 0001011060 ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember ASNB:MichaelAdamsMember 2017-08-16 2017-08-17 0001011060 ASNB:CommonStockOptionsMember ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember ASNB:DirectorsCertainEmployeesAndOneConsultantMember 2017-08-16 2018-12-13 0001011060 ASNB:TwoThousandAndSeventeenNonQualifiedEquityIncentivePlanMember 2019-12-31 0001011060 2017-08-16 2017-08-17 0001011060 2018-08-15 2018-08-16 0001011060 2018-12-12 2018-12-13 0001011060 us-gaap:SalesRevenueNetMember ASNB:TwoCustomersMember 2019-10-01 2019-12-31 0001011060 us-gaap:SalesRevenueNetMember ASNB:ThreeCustomersMember 2018-10-01 2018-12-31 0001011060 us-gaap:SalesRevenueNetMember ASNB:ThreeCustomersMember 2019-04-01 2019-12-31 0001011060 us-gaap:SalesRevenueNetMember ASNB:ThreeCustomersMember 2018-04-01 2018-12-31 0001011060 ASNB:TwoCustomersMember 2019-12-31 0001011060 ASNB:TwoCustomersMember 2019-04-01 2019-12-31 0001011060 ASNB:OneCustomersMember 2019-03-31 0001011060 ASNB:OneCustomersMember 2018-04-01 2019-03-31 0001011060 ASNB:TwoCustomersMember 2019-03-31 0001011060 ASNB:AssetPurchaseAgreementMember 2019-11-24 2019-11-25 0001011060 us-gaap:CommonStockMember 2019-04-01 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q false 2019-12-31 Q3 2020 --03-31 AdvanSource Biomaterials Corp 0001011060 Yes Non-accelerated Filer true false Yes false 28262371 447000 172000 213000 483000 100000 61000 343000 185000 2067000 2091000 113000 3000 3183000 2934000 47000 47000 3230000 2981000 497000 467000 446000 342000 191000 24000 140000 3624000 3509000 3624000 3509000 28000 21000 38610000 38427000 -394000 -528000 -885000 -976000 -932000 -416000 -445000 -433000 21000 21000 38404000 38404000 -39280000 -39371000 -30000 -30000 21000 38423000 -39346000 -30000 21000 38423000 -38830000 -30000 21000 21000 38427000 38427000 -38946000 -38863000 -30000 -30000 21000 38427000 -38851000 -30000 28000 38610000 -39002000 -30000 3230000 2981000 5000 5000 0.001 0.001 5000000 5000000 0.001 0.001 50000000 50000000 3000000 28339063 28339063 28262371 28262371 76692 76692 -185000 -152000 -54000 -65000 -185000 -152000 -54000 -65000 -185000 -152000 -54000 -65000 129000 602000 570000 -86000 -56000 450000 516000 -151000 -91000 25000 83000 12000 -91000 25000 516000 83000 12000 -151000 -0.01 -0.01 -0.01 -0.00 -0.01 0.03 0.03 0.00 0.00 0.02 0.02 -0.01 -0.01 -0.01 0.00 -0.00 -0.01 0.03 0.03 0.00 0.00 0.02 0.02 -0.01 22157000 21491000 21491000 23498000 22157000 22627000 22711000 23498000 19000 270000 -234000 -158000 127000 -110000 30000 -9000 104000 -28000 167000 -40000 118000 -317000 107000 295000 225000 -22000 50000 -5000 190000 275000 -27000 447000 172000 120000 93000 278000 280000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>1. Business Description</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On January 31, 2020 (the &#8220;Closing Date&#8221;), we completed the sale of substantially all of our assets (the &#8220;Asset Sale&#8221;) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (&#8220;MCPP&#8221;). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Prior to the Closing Date, our corporate, development and manufacturing operations were located in a leased facility in Wilmington, Massachusetts.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>2. Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2019, we recorded our normal business operations as discontinued operations as a result of the previously described Asset Sale. Within ninety (90) days of the Closing Date, the Board of Directors is expected to declare a distribution of the net proceeds from the Asset Sale, after making adjustments for (i) collection of accounts receivable retained as of January 31, 2020, (ii) payment of accounts payable assumed as of January 31, 2020; and (iii) retention of a reasonable amount of cash for anticipated future obligations. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, management believes there is substantial doubt about our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Management is seeking to identify an operating company for the purpose of effecting a merger or business combination, or to acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target&#8217;s management to have proven its abilities or effectiveness, or the lack of an established market for the target&#8217;s products or services, or the inability to reach profitability in the next few years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>3. Interim Financial Statements and Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three and nine months ended December 31, 2019 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The information contained in this quarterly report on Form 10-Q should be read in conjunction with our audited financial statements included in our annual report on Form 10-K, as of and for the year ended March 31, 2019 as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments, which are evaluated on an ongoing basis, and that affect the amounts reported in our unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to revenue recognition, allowance for doubtful accounts, inventory reserves, useful lives and valuation of property and equipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our significant accounting policies are described in Note 3 to the audited financial statements as of March 31, 2019 which are included in our Annual Report on Form 10-K as filed with the SEC on August 23, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Reclassifications</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. these reclassifications had no effect on the previously reported financial position or results of operations.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>4. Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on our accounting and reporting. We believe that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on our accounting or reporting or that such impact will not be material to our financial position, results of operations and cash flows when implemented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Recent accounting pronouncements are included in Note 3 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2019.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>5. Held for Sale Assets and Liabilities and Discontinued Operations</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On November 25, 2019, we entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (&#8220;MCPP&#8221;), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the &#8220;Asset Sale&#8221;). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020 (the &#8220;Closing Date&#8221;), we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Pursuant to the Purchase Agreement, we sold all of our inventory; property, plant and equipment; and intangible assets, including but not limited to all intellectual property, business know-how, customer lists and related contracts, and all other assets necessary to operate our advanced polymer business. All cash; accounts receivable; prepaid expenses; deposits on facility lease; accounts payable; and accrued expenses as of the Closing Date were retained by us. We believe the Asset Sale meets the accounting criteria for held for sale assets, accordingly, the following presents the components of held for sale assets as of December 31, 2019:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Held for Sale Assets</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Assets of Discontinued Operations Held for Sale</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%"><font style="font-size: 10pt">Inventories, net</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">271</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">248</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Property, plant and equipment, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,749</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,791</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing costs, net</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">47</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">52</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Assets of discontinued operations held for sale</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,067</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Raw materials</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">129</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">121</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Work in progress</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">48</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Finished goods</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">107</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">79</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total inventories, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">271</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">248</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Property, plant and equipment which were included in held for sale assets consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Land</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Building</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,705</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,705</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Machinery, equipment and tooling</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,248</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,248</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Furniture, fixtures and office equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">285</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">285</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Office equipment under capital lease</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,752</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,751</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,003</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,960</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Property, plant and equipment, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,749</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,791</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our lease with the independent third-party owner of the land and building was assigned to MCPP at which time all of our obligations with respect to the lease agreement were relieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Held for Sale Liabilities</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. For accounting purposes, this sale-leaseback transaction was accounted for under the financing method, rather than as a completed sale. Under the financing method, we included the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (&#8220;MCPP&#8221;), which was completed on January 31, 2020, our lease with the independent third-party owner of the building was assigned to MCPP. As a result, we recorded the aggregate financing obligation and accrued interest on financing obligation of approximately $2,141,000 and $2,154,000 was recorded as liabilities held for sale in our balance sheet. Subsequent to the January 31, 2020, we had no further obligations with respect to the lease agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Discontinued Operations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As a result of the Asset Sale, we discontinued operating as a developer, manufacturer, marketer and seller of advanced polymers on the Closing Date. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. Accordingly, the results of our operations are reported as discontinued operations for all periods are presented below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Results of Discontinued Operations</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Three Months Ended December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Three Months Ended December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Nine Months Ended December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the Nine Months Ended December 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Revenues:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; padding-left: 10pt"><font style="font-size: 10pt">Product sales</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">457</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">608</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">1,632</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 12%; text-align: right"><font style="font-size: 10pt">1,564</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">License and royalty fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">351</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">281</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">803</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">708</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt"><font style="font-size: 10pt">Total revenues</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">808</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">889</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,435</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,272</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cost of sales</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">194</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">259</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">641</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">670</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Gross profit</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">614</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">630</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,794</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,602</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Operating expenses:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Research, development and regulatory</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">103</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">253</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Selling, general and administrative</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">495</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">271</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,049</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">847</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total operating expenses</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">598</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">348</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,329</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,100</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Income (loss) from discontinued operations</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">16</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">282</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">465</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">502</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other income (expense) from discontinued operations, net:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Gain on disposition of sales-leaseback assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">34</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">382</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">34</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">382</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt"><font style="font-size: 10pt">Interest expense</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(136</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(94</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(370</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(282</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 20pt"><font style="font-size: 10pt">Other income (expense) from discontinued operations, net</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(102</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">288</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(336</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">100</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Income (loss) from discontinued operations before provision for income taxes</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(86</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">570</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">129</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">602</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Provision for income taxes</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net income (loss) from discontinued operations</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(86</font></td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">570</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">129</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">602</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Net income (loss) from discontinued operations per common share:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Basic</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.01</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(0.00</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.01</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Shares used in computing net income from discontinued operations per common share:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Basic</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">23,498</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">21,491</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,157</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">21,491</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Diluted</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">23,498</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,711</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,157</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,627</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Continuing Operations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our loss from continuing operations represents those costs necessary to operate a public company in the approximate amount of $65,000 and $185,000 during the three and nine months ended December 31, 2019, respectively; and $54,000 and $152,000 during the three and nine months ended December 31, 2018, respectively. These costs were composed of accounting fees, professional fees, regulatory fees, board of directors fees, and director and officer liability insurance premiums.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>6. Related Party Transactions</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the &#8220;Carroll Note&#8221;). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the &#8220;Affiliate&#8221;) in the principal amount of $25,000 (the &#8220;First Affiliate Note&#8221;). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the &#8220;Second Affiliate Note&#8221;). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the &#8220;Affiliate Notes&#8221;) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the &#8220;2017 Option Plan&#8221;). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>7. Income Per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per common share are based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted income per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 410,000 shares and 410,000 shares for the three and nine months ended December 31, 2019. Potentially dilutive shares, which were included in the diluted income per share calculations for the three and nine months ended December 31, 2018 were 1,220,008 shares and 1,137,025 shares.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>8. Income Taxes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are required to file federal and state income tax returns in the United States. The preparation of these tax returns requires us to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by us. In consultation with our tax advisors, we base our tax returns on interpretations that are believed to be reasonable under the circumstances. The tax returns, however, are subject to routine reviews by the various federal and state taxing authorities in the jurisdictions in which we file tax returns. As part of these reviews, a taxing authority may disagree with respect to the income tax positions taken by us (&#8220;uncertain tax positions&#8221;) and, therefore, may require us to pay additional taxes. As required under applicable accounting rules, we accrue an amount for our estimate of additional income tax liability, including interest and penalties, which we could incur as a result of the ultimate or effective resolution of the uncertain tax positions. We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We had no income tax credits for the three and nine months ended December 31, 2019 and 2018. The effective tax rates for the three and nine months ended December 31, 2019 was 21.0%. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>9. Promissory Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the &#8220;Carroll Note&#8221;). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the &#8220;Affiliate&#8221;) in the principal amount of $25,000 (the &#8220;First Affiliate Note&#8221;). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the &#8220;Second Affiliate Note&#8221;). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the &#8220;Affiliate Notes&#8221;) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the &#8220;2017 Option Plan&#8221;). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>10. Long-Term Financing Obligation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. In addition, we provided, as collateral, a security interest in all furnishings, fixtures and equipment owned and used by us, having a net book value of approximately $0 as of December 31, 2019. For accounting purposes, the provision of such collateral constitutes continuing involvement with the associated property. Due to this continuing involvement, this sale-leaseback transaction is accounted for under the financing method, rather than as a completed sale. Under the financing method, we include the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. Through December 2018, interest on the financing obligation exceeded the minimum lease payments, accordingly the principal remains constant through that date. After December 2018, the minimum lease payment will exceed interest and principal will be reduced by the excess of minimum lease payment over interest. The building, building improvements and land remain on the condensed balance sheet and the building and building improvements will continue to be depreciated over their remaining useful lives. Payments made under the lease are applied as payments of imputed interest and deemed principal on the underlying financing obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (&#8220;MCPP&#8221;), which was completed on January 31, 2020 (the &#8220;Closing Date&#8221;), our lease with the independent third-party owner of the building was assigned to MCPP. As a result, subsequent to the Closing Date, we have no further obligations with respect to the lease agreement.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>11. Stockholders&#8217; Deficit</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Common Stock Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On July 22, 2015, we engaged the services of a financial and strategic advisor (the &#8220;Advisor&#8221;) whose services include, but are not limited to, financial advice, strategic advice and investment banking services. In connection with this engagement, we agreed to compensate the Advisor approximately $4,000 per quarter for a one-year period and we issued them a warrant to purchase 830,500 shares of our common stock at an exercise price of $0.03 per share, the approximate fair value of our common stock on the date of the engagement. The warrant is exercisable at any time until July 21, 2025. The warrant was valued at approximately $28,000 using the Black-Scholes model and treated as permanent equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On November 27, 2019, the Advisor exercised the warrant to purchase 830,500 shares of our common stock in consideration of approximately $25,000 in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>Common Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Stock Option Plan. In consideration for the exercise of these options we received approximately $40,000 in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the &#8220;Adams Option&#8221;) at an exercise price of $0.06 per share pursuant to the 2017 Non-Qualified Equity Incentive Plan (the &#8220;2017 Plan&#8221;). On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the &#8220;Grantees&#8221;) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>13. Concentrations of Credit Risk and Major Customers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For the three months ended December 31, 2019 and 2018, two customers represented approximately 49% of our total revenues from discontinued operations and three customers represented approximately 66% of our total revenues, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For the nine months ended December 31, 2019 and 2018, three customers represented approximately 52% of our total revenues from discontinued operations and three customers represented approximately 53% of our total revenues, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of December 31, 2019, we had accounts receivable-trade of approximately $100,000, or 47%, due from two customers. As of March 31, 2019, we had accounts receivable-trade of approximately $61,000, or 13%, due from one customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of December 31, 2019 and March 31, 2019, we had approximately $343,000 due from two customers and $185,000 due from two customers, respectively, related to receivables on license fees and royalties. These amounts are classified as accounts receivable-other in our balance sheets.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>14. Legal Proceedings</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>15. Subsequent Events</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We evaluated all events or transactions that occurred after the balance sheet date through the date when we filed these financial statements and, other than as discussed below, we determined that we did not have any other material recognizable subsequent events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On November 25, 2019, we entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (&#8220;MCPP&#8221;), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the &#8220;Asset Sale&#8221;). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020, we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.</p> 140000 5000 21491000 21491000 21491000 21491000 21491000 21491000 21491000 28262000 19000 19000 165000 6000 159000 5941000 25000 1000 24000 830000 30000 30000 39002000 38946000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Activity under the 2003 Plan for the nine months ended December 31, 2019 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Options</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-Average Exercise Price per Share</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-<br /> Average Remaining Contractual<br /> Term in Years</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate Intrinsic Value&#160;<i>(in thousands)</i></b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding as of April 1, 2019</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,788,750</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.03</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(656,250</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cancelled or forfeited</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(722,500</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options vested or expected to vest as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In determining the fair value of the options granted pursuant to the 2017 Plan, we utilized the Black-Scholes pricing model utilizing the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>August 17, 2017 Option Grants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>August 16, 2018 Option Grants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 13, 2018 Option Grants</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Total shares granted</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,600,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">750,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Option exercise price per share</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.040</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.060</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Grant date fair market value per share</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.046</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.059</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected term of option in years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.0</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.69</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Assets of Discontinued Operations Held for Sale</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%"><font style="font-size: 10pt">Inventories, net</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">271</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">248</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Property, plant and equipment, net</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,749</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,791</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing costs, net</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">47</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">52</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Assets of discontinued operations held for sale</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,067</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt">&#160;</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%"><font style="font-size: 10pt">Raw materials</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">129</font></td> <td style="width: 1%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">121</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Work in progress</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">48</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Finished goods</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">107</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">79</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total inventories, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">271</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">248</font></td></tr> </table> <p style="margin: 0pt">&#160;</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><i>(in thousands)</i></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2019</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Land</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Building</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,705</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,705</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Machinery, equipment and tooling</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,248</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,248</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Furniture, fixtures and office equipment</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">285</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">285</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Office equipment under capital lease</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">13</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,752</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,751</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,003</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(2,960</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Property, plant and equipment, net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,749</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,791</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Accordingly, the results of our operations are reported as discontinued operations for all periods are presented below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Results of Discontinued Operations</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Three Months Ended December 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Three Months Ended December 31, 2018</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Nine Months Ended December 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the Nine Months Ended December 31, 2018</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif"><i>(in thousands)</i></font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Revenues:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Product sales</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">457</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">608</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,632</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,564</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">License and royalty fees</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">351</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">281</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">803</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">708</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt"><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">808</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">889</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,435</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,272</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cost of sales</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">194</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">259</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">641</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">670</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">614</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">630</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,794</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,602</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Research, development and regulatory</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">103</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">280</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Selling, general and administrative</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">495</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">271</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,049</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">847</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt"><font style="font: 10pt Times New Roman, Times, Serif">Total operating expenses</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">598</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">348</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,329</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,100</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Income (loss) from discontinued operations</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">282</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">465</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">502</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense) from discontinued operations, net:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Gain on disposition of sales-leaseback assets</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">382</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">34</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">382</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Interest expense</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(136</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(94</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(370</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(282</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expense) from discontinued operations, net</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(102</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">288</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(336</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Income (loss) from discontinued operations before provision for income taxes</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(86</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">570</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">129</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">602</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Provision for income taxes</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Net income (loss) from discontinued operations</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(86</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">570</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">129</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">602</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Net income (loss) from discontinued operations per common share:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Basic</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.01</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Diluted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.01</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.03</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Shares used in computing net income from discontinued operations per common share:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Basic</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,498</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,491</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">22,157</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21,491</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Diluted</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">23,498</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">22,711</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">22,157</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">22,627</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> 7250000 7250000 1150000 567000 483000 100000 2000000 1986000 155000 168000 2141000 2490000 2536000 2154000 185000 152000 54000 65000 47000 52000 2067000 2091000 271000 248000 129000 121000 35000 48000 107000 79000 1749000 1791000 4752000 4751000 500000 500000 2705000 2705000 1248000 1248000 285000 285000 13000 13000 -3003000 -2960000 2435000 2272000 889000 808000 457000 608000 351000 281000 1632000 1564000 803000 708000 0.01 0.03 0.03 -0.00 0.01 0.03 0.03 -0.00 129000 602000 570000 -86000 129000 602000 570000 -86000 -336000 100000 288000 -102000 34000 382000 382000 34000 465000 502000 282000 16000 1329000 1100000 348000 598000 1049000 847000 271000 495000 280000 253000 77000 103000 1794000 1602000 630000 614000 641000 670000 259000 194000 22157000 21491000 21491000 23498000 22157000 22627000 22711000 23498000 25000 25000 100000 The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. 0.10 0.10 0.12 15000 5000 15000 0 25000 0 100000 125000 3000 2083333 656250 2500000 2083333 4050000 7000000 2500000 4050000 5600000 750000 200000 125000 0 1000 1000 2000 4000 4000 10000 10000 On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. 0.21 0 1000 1000 2000 4000 4000 10000 10000 370000 282000 94000 136000 2000000 Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. 0 1986000 1986000 4000 830500 830500 0.03 28000 25000 40000 0.06 0.04 0.06 0.06 0.06 0.040 0.060 0.165 125000 416667 291667 2910000 7000000 P10Y 6550000 450000 410000 1788750 410000 410000 0.27 0.20 0.29 0.27 0.27 1000 20000 1000 1000 0.06 0.046 0.059 P10Y P2Y P1Y 1.00 1.00 1.00 0.0000 0.0000 0.0000 0.0100 0.0000 0.0269 0.49 0.66 0.52 0.53 0.47 0.13 343000 185000 7250000 7250000 1150000 567000 483000 100000 656250 722500 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>12. Stock-Based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In October 2003, our shareholders approved the AdvanSource 2003 Stock Option Plan (the &#8220;2003 Plan&#8221;), which authorizes the issuance of 3,000,000 shares of common stock. Under the terms of the Plan, the exercise price of Incentive Stock Options issued under the Plan must be equal to the fair market value of the common stock at the date of grant. In the event that Non-Qualified Options are granted under the Plan, the exercise price may be less than the fair market value of the common stock at the time of the grant (but not less than par value). Total shares of common stock registered under the 2003 Plan are 7,000,000 shares. Normally, options granted expire ten years from the grant date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Activity under the 2003 Plan for the nine months ended December 31, 2019 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of Options</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-Average Exercise Price per Share</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-<br /> Average Remaining Contractual<br /> Term in Years</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate Intrinsic Value&#160;<i>(in thousands)</i></b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding as of April 1, 2019</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,788,750</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.20</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.03</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(656,250</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cancelled or forfeited</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(722,500</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.29</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Options vested or expected to vest as of December 31, 2019</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">410,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.23</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on December 31, 2019 of $0.165 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on December 31, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Plan. In consideration for the exercise of these options we received approximately $40,000 in cash. There were no stock options exercised under the 2003 Plan for the three and nine months ended December 31, 2018. As of December 31, 2019, there were no shares remaining to be granted under the 2003 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">For the three and nine months ended December 31, 2019 and 2018, we recorded no stock-based compensation expense for options pursuant to the 2003 Plan. As of December 31, 2019, we had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On August 14, 2017, our board of directors approved and adopted the 2017 Non-Qualified Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which authorized the grant of non-qualified stock options exercisable into a maximum of 7,000,000 shares of our common stock. Under the terms of the 2017 Plan, the exercise price of stock options issued under the 2017 Plan must be equal to the fair market value of the common stock at the date of grant. Options granted expire ten years from the grant date. From August 17, 2017 through December 13, 2018, the board of directors approved the grant of stock options to certain directors, employees and a consultant which were immediately vested and exercisable into a total of 6,550,000 shares of our common stock. There were no additional stock options granted pursuant to the 2017 Plan for the period subsequent to December 31, 2018. In determining the fair value of the options granted pursuant to the 2017 Plan, we utilized the Black-Scholes pricing model utilizing the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>August 17, 2017 Option Grants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>August 16, 2018 Option Grants</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 13, 2018 Option Grants</b></font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%"><font style="font: 10pt Times New Roman, Times, Serif">Total shares granted</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,600,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">750,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Option exercise price per share</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.040</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.060</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Grant date fair market value per share</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.06</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.046</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.059</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected term of option in years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10.0</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Risk free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.69</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the &#8220;Adams Option&#8221;) at an exercise price of $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the &#8220;Grantees&#8221;) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of December 31, 2019, there were 450,000 shares available to grant pursuant to the 2017 Plan and no options outstanding or exercisable.</p> 410000 1137025 1220008 410000 P2Y11D P2M23D P2M23D P2M23D EX-101.SCH 6 asnb-20191231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Description link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Interim Financial Statements and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Per Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Promissory Notes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Long-Term Financing Obligation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Concentrations of Credit Risk and Major Customers link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Description (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Components of Assets Held-for-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Income Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Promissory Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Long-Term Financing Obligation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Pricing Model Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Concentrations of Credit Risk and Major Customers (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 asnb-20191231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 asnb-20191231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 asnb-20191231_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Treasury Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Legal Entity [Axis] Mitsubishi Chemical Performance Polymers, Inc [Member] Related Party [Axis] Independent Third-Party [Member] Inventory [Axis] Raw Materials [Member] Work in Progress [Member] Finished Goods [Member] Property, Plant and Equipment, Type [Axis] Land [Member] Building [Member] Machinery, Equipment and Tooling [Member] Furniture, Fixtures and Office Equipment [Member] Office Equipment Under Capital Lease [Member] Product and Service [Axis] Product Sales [Member] License and Royalty Fees [Member] Khristine Carroll [Member] Debt Instrument [Axis] Carroll Note [Member] Michael Adams [Member] First Affiliate Note [Member] Second Affiliate Note [Member] Affiliate Notes [Member] Plan Name [Axis] 2017 Non-Qualified Equity Incentive Plan [Member] Common Stock Warrants [Member] Advisor [Member] Common Stock Options [Member] 2003 Stock Option Plan [Member] Directors and Certain Employees [Member] Title of Individual [Axis] Directors, Certain Employees and One Consultant [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Board of Directors [Member] Directors, Certain Employees and a Consultant [Member] Concentration Risk Benchmark [Axis] Revenue [Member] Concentration Risk Type [Axis] Two Customers [Member] Three Customers [Member] One Customers [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable-trade, net of allowance of $5 as of December 31, 2019 and March 31, 2019 Accounts receivable-other Assets held for sale Prepaid expenses and other current assets Total current assets Other assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable Accrued expenses Customer advance Liabilities held for sale Related party notes payable Total current liabilities Total liabilities Commitments and contingencies (See Note 14) Stockholders' deficit: Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2019 and March 31, 2019 Common stock; $.001 par value; 50,000,000 shares authorized; 28,339,063 shares issued; and 28,262,371 shares outstanding as of December 31, 2019 and March 31, 2019 Additional paid-in capital Accumulated deficit Treasury stock, 76,692 shares at cost as of December 31, 2019 and March 31, 2019 Total stockholders' deficit Total liabilities and stockholders' deficit Allowance for doubtful accounts receivable Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock shares Income Statement [Abstract] Operating expenses Loss from continuing operations before provision for income taxes Provision for income taxes Loss from continuing operations Income (loss) from discontinued operations, net of income taxes Net income (loss) Income per common share - basic: Continuing operations Discontinued operations Net income per share - basic Income per common share - diluted: Continuing operations Discontinued operations Net income per share - diluted Shares used in computing net income per common share: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Net income (loss) Stock-based compensation Common stock issued on exercise of stock options Common stock issued on exercise of stock options, shares Common stock on exercise of warrants Common stock on exercise of warrants, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Loss from continuing operations Income from discontinued operations Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities: Stock-based compensation Changes in assets and liabilities: Accounts receivable-trade Accounts receivable-other Prepaid expenses and other current assets Accounts payable Accrued expenses Customer advance Net cash flows provided by (used in) operating activities of continuing operations Net cash flows provided by operating activities of discontinued operations Net cash flows provided by (used in) operating activities Cash flows from financing activities: Issuance of common stock Repayment of related party notes payable Net cash flows provided by (used in) financing activities Net change in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Income taxes paid Interest paid Accounting Policies [Abstract] Business Description Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Interim Financial Statements And Basis Of Presentation Interim Financial Statements and Basis of Presentation Accounting Changes and Error Corrections [Abstract] Recent Accounting Pronouncements Discontinued Operations and Disposal Groups [Abstract] Held for Sale Assets and Liabilities and Discontinued Operations Related Party Transactions [Abstract] Related Party Transactions Earnings Per Share [Abstract] Income Per Share Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] Promissory Notes Long-Term Financing Obligation Equity [Abstract] Stockholders' Deficit Share-based Payment Arrangement [Abstract] Stock-Based Compensation Risks and Uncertainties [Abstract] Concentrations of Credit Risk and Major Customers Commitments and Contingencies Disclosure [Abstract] Legal Proceedings Subsequent Events [Abstract] Subsequent Events Schedule of Components of Assets Held-for-Sale Schedule of Discontinued Operations Schedule of Stock Option Activity Schedule of Black-Scholes Pricing Model Assumptions Purchase price of asset Transaction and legal costs Facility related obligations Contingent facility maintenance costs Inventories, net Inventory held for sale Proceeds from land and building Financing obligation Accrued interest on financing obligation Loss from continuing operations Property, plant and equipment, net Deferred financing costs, net Assets of discontinued operations held for sale Property, plant and equipment, gross Less: accumulated depreciation Total revenues Cost of sales Gross profit Research, development and regulatory Selling, general and administrative Total operating expenses Income (loss) from discontinued operations Gain on disposition of sales-leaseback assets Interest expense Other income (expense) from discontinued operations, net Income (loss) from discontinued operations before provision for income taxes Provision for income taxes Net income (loss) from discontinued operations Net income (loss) from discontinued operations per common share: Basic Net income (loss) from discontinued operations per common share: Diluted Shares used in computing net income from discontinued operations per common share: Basic Shares used in computing net income from discontinued operations per common share: Diluted Issuance of promissory note Note due date description Note interest rate Repayments of promissory note Note principal balance outstanding Commitment fee Number of stock options shares granted Purchase price upon exercise of stock options Interest expense Potentially dilutive shares, excluded from the diluted income per share Income tax credits Effective income tax rate Effective income tax rate description Interest expense Proceeds of sale of land and building Initial minimum lease term Lease back description Fixtures and equipment net book value Compensate amount Number of warrant purchase shares of common stock Warrant exercise price Warrant, value Common stock in consideration cash Number of shares exercised options to purchase Option exercise price Principal balance due on Affiliate Notes Options remaining exercisable shares Number of shares cashless exercise of common stock Number of shares common stock Consideration cash Stock-based compensation expense Unrecognized compensation cost Option granted expired term Number of stock options vested and exerciseable Number of shsres available to grant Number of Options Outstanding Beginning Balance Number of Options Granted Number of Options Exercised Number of Options Cancelled or Forfeited Number of Options Outstanding Ending Balance Number of Options Exercisable Number of Options Vested or Expected to Vest Weighted-average Exercise Price Per Share Outstanding Beginning Balance Weighted-average Exercise Price Per Share Granted Weighted-average Exercise Price Per Share Exercised Weighted-average Exercise Price Per Share Cancelled or Forfeited Weighted-average Exercise Price Per Share Outstanding Ending Balance Weighted-average Exercise Price Per Share Exercisable Weighted-average Exercise Price Per Share Vested or Expected to Vest Weighted-average Remaining Contractual Term in Years Outstanding, Beginning Weighted-average Remaining Contractual Term in Years Outstanding, Ending Weighted-average Remaining Contractual Term in Years Exercisable Weighted-average Remaining Contractual Term in Years Vested or Expected to Vest Aggregate Intrinsic Value Outstanding Beginning Aggregate Intrinsic Value Outstanding Ending Aggregate Intrinsic Value Exercisable Aggregate Intrinsic Value, Vested or Expected to Vest Total shares granted Option exercise price per share Grant date fair market value per share Expected term of option in years Expected volatility Expected dividend rate Risk free interest rate Concentrations of credit risk percentage Accounts receivable-trade Due from customer Payment of sale of asset Immediately disbursed amount Legal cost Facility related obligations Contingent facility maintenance costs Assets held for sale. Customer advance. Liabilities held for sale. Customer advance. Interim Financial Statements and Basis of Presentation [Text Block] Common stock on exercise of warrants. Common stock on exercise of warrants, shares. Asset Purchase Agreement [Member] Mitsubishi Chemical Performance Polymers, Inc [Member] Accrued interest on financing obligation. Independent Third-Party [Member] Disposal group including discontinued operation deferred financing costs. Disposal group including discontinued operations assets held for sale. Disposal group including discontinued operation property plant and equipment gross. Disposal group including discontinued operation property plant and equipment gross. Work in Progress [Member] Finished Goods [Member] Office Equipment Under Capital Lease [Member] Disposal group including discontinued operation research development and regulatory. Disposal group including discontinued operation gain on disposition of sales-leaseback assets. Product Sales [Member] License and Royalty Fees [Member] Income loss from discontinued operations shares computing per common share basic. Income loss from discontinued operations shares computing per common share diluted. Khristine Carroll [Member] Carroll Note [Member] Michael Adams [Member] First Affiliate Note [Member] Second Affiliate Note [Member] Affiliate Notes [Member] 2017 Non-Qualified Equity Incentive Plan [Member] Compensation amount. Advisor [Member] Common Stock Warrants [Member] Common stock in consideration cash. Common Stock Options [Member] 2003 Stock Option Plan [Member] Directors and Certain Employees [Member] Options remaining exercisable shares. Number of shares cashless exercise of common stock. August 17, 2017 through December 13, 2018 [Member] Directors, Certain Employees and One Consultant [Member] Board of Directors [Member] Number of stock options vested and exerciseable. Directors, Certain Employees and a Consultant [Member] Number of shsres available to grant. Weighted Average Remaining Contractual Life In Years Outstanding Beginning. Number of options vested or expected to vest. Weighted-average exercise price per share vested or expected to vest. Weighted-average exercise price per share vested or expected to vest. Aggregate intrinsic value, vested or expected to vest. Grant date fair market value per share. Two Customers [Member] Three Customers [Member] One Customers [Member] Facility related obligations. Immediately disbursed amount. Assets, Current Assets Liabilities, Current Liabilities Retained Earnings (Accumulated Deficit) Treasury Stock, Value Stockholders' Equity Attributable to Parent Liabilities and Equity Income (Loss) from Continuing Operations, Per Diluted Share Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Shares, Outstanding Increase (Decrease) in Accounts and Other Receivables Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities IncreaseDecreaseInCustomerAdvance Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities Repayments of Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Disposal Group, Including Discontinued Operation, Interest Expense Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Interest Expense, Debt Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value AggregateIntrinsicValuesVestedOrExpectedToVest FacilityRelatedObligations Cost, Maintenance EX-101.PRE 10 asnb-20191231_pre.xml XBRL PRESENTATION FILE ZIP 11 0001493152-20-005627-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-005627-xbrl.zip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htm IDEA: XBRL DOCUMENT v3.20.1
Income Per Share
 9 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Income Per Share

7. Income Per Share

 

Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per common share are based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted income per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 410,000 shares and 410,000 shares for the three and nine months ended December 31, 2019. Potentially dilutive shares, which were included in the diluted income per share calculations for the three and nine months ended December 31, 2018 were 1,220,008 shares and 1,137,025 shares.
XML 13 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Deficit
 9 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Stockholders' Deficit

11. Stockholders’ Deficit

 

Common Stock Warrants

 

On July 22, 2015, we engaged the services of a financial and strategic advisor (the “Advisor”) whose services include, but are not limited to, financial advice, strategic advice and investment banking services. In connection with this engagement, we agreed to compensate the Advisor approximately $4,000 per quarter for a one-year period and we issued them a warrant to purchase 830,500 shares of our common stock at an exercise price of $0.03 per share, the approximate fair value of our common stock on the date of the engagement. The warrant is exercisable at any time until July 21, 2025. The warrant was valued at approximately $28,000 using the Black-Scholes model and treated as permanent equity.

 

On November 27, 2019, the Advisor exercised the warrant to purchase 830,500 shares of our common stock in consideration of approximately $25,000 in cash.

 

Common Stock Options

 

On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Stock Option Plan. In consideration for the exercise of these options we received approximately $40,000 in cash.

 

On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the “Adams Option”) at an exercise price of $0.06 per share pursuant to the 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”). On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the “Grantees”) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.
XML 14 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events (Details Narrative) - Asset Purchase Agreement [Member] - USD ($)
$ in Thousands
Jan. 31, 2020
Nov. 25, 2019
Payment of sale of asset   $ 7,250
Subsequent Event [Member]    
Payment of sale of asset $ 7,250  
Immediately disbursed amount 1,150  
Legal cost 567  
Facility related obligations 483  
Contingent facility maintenance costs $ 100  
XML 15 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 10 Months Ended 16 Months Ended
Dec. 05, 2019
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Aug. 14, 2017
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Oct. 31, 2003
Dec. 13, 2018
Mar. 31, 2019
Common stock, shares authorized             50,000,000       50,000,000
Option exercise price   $ 0.060 $ 0.040 $ 0.06              
Number of shares exercised options to purchase   200,000 750,000 5,600,000              
Stock-based compensation expense             $ 19      
Unrecognized compensation cost                    
Common Stock [Member]                      
Option exercise price             $ 0.165        
Common Stock Options [Member]                      
Number of shares exercised options to purchase 4,050,000              
Number of shares cashless exercise of common stock 2,910,000                    
Common Stock Options [Member] | Michael Adams [Member]                      
Number of shares exercised options to purchase 2,083,333                    
Principal balance due on Affiliate Notes $ 125                    
Options remaining exercisable shares 416,667                    
Number of shares cashless exercise of common stock 291,667                    
Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member] | Maximum [Member]                      
Option exercise price                   $ 0.06  
Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member] | Minimum [Member]                      
Option exercise price                   $ 0.04  
2003 Stock Option Plan [Member]                      
Common stock, shares authorized                 3,000,000    
Number of shares common stock                 7,000,000    
Stock-based compensation expense                  
2003 Stock Option Plan [Member] | Common Stock Options [Member] | Directors and Certain Employees [Member]                      
Number of shares exercised options to purchase 656,250                    
Consideration cash $ 40                    
2017 Non-Qualified Equity Incentive Plan [Member]                      
Number of shsres available to grant             450,000        
2017 Non-Qualified Equity Incentive Plan [Member] | Board of Directors [Member]                      
Option granted expired term         10 years            
2017 Non-Qualified Equity Incentive Plan [Member] | Board of Directors [Member] | Maximum [Member]                      
Number of shares exercised options to purchase         7,000,000            
2017 Non-Qualified Equity Incentive Plan [Member] | Michael Adams [Member]                      
Option exercise price       $ 0.06              
Number of shares exercised options to purchase       2,500,000              
2017 Non-Qualified Equity Incentive Plan [Member] | Directors, Certain Employees and a Consultant [Member]                      
Number of stock options vested and exerciseable                   6,550,000  
2017 Non-Qualified Equity Incentive Plan [Member] | Common Stock Options [Member] | Michael Adams [Member]                      
Option exercise price       $ 0.06              
Number of shares exercised options to purchase       2,500,000              
2017 Non-Qualified Equity Incentive Plan [Member] | Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member]                      
Number of shares exercised options to purchase                   4,050,000  
XML 16 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]        
Income tax credits
Effective income tax rate     21.00%  
Effective income tax rate description     On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings.  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Mar. 31, 2019
Current assets:    
Cash $ 447 $ 172
Accounts receivable-trade, net of allowance of $5 as of December 31, 2019 and March 31, 2019 213 483
Accounts receivable-other 343 185
Assets held for sale 2,067 2,091
Prepaid expenses and other current assets 113 3
Total current assets 3,183 2,934
Other assets 47 47
Total assets 3,230 2,981
Current liabilities:    
Accounts payable 497 467
Accrued expenses 446 342
Customer advance 191 24
Liabilities held for sale 2,490 2,536
Related party notes payable 140
Total current liabilities 3,624 3,509
Total liabilities 3,624 3,509
Commitments and contingencies (See Note 14)
Stockholders' deficit:    
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2019 and March 31, 2019
Common stock; $.001 par value; 50,000,000 shares authorized; 28,339,063 shares issued; and 28,262,371 shares outstanding as of December 31, 2019 and March 31, 2019 28 21
Additional paid-in capital 38,610 38,427
Accumulated deficit (39,002) (38,946)
Treasury stock, 76,692 shares at cost as of December 31, 2019 and March 31, 2019 (30) (30)
Total stockholders' deficit (394) (528)
Total liabilities and stockholders' deficit $ 3,230 $ 2,981
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:    
Loss from continuing operations $ (185) $ (152)
Income from discontinued operations 129 602
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:    
Stock-based compensation 19
Changes in assets and liabilities:    
Accounts receivable-trade 270 (234)
Accounts receivable-other (158) 127
Prepaid expenses and other current assets (110)
Accounts payable 30 (9)
Accrued expenses 104 (28)
Customer advance 167 (40)
Net cash flows provided by (used in) operating activities of continuing operations 118 (317)
Net cash flows provided by operating activities of discontinued operations 107 295
Net cash flows provided by (used in) operating activities 225 (22)
Cash flows from financing activities:    
Issuance of common stock 190
Repayment of related party notes payable (140) (5)
Net cash flows provided by (used in) financing activities 50 (5)
Net change in cash 275 (27)
Cash at beginning of period 172 120
Cash at end of period 447 93
Supplemental disclosure of cash flow information:    
Income taxes paid
Interest paid $ 278 $ 280
XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 184 280 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advbiomaterials.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://advbiomaterials.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://advbiomaterials.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://advbiomaterials.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statement of Stockholders' Deficit (Unaudited) Sheet http://advbiomaterials.com/role/StatementOfStockholdersDeficit Statement of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows (Unaudited) Sheet http://advbiomaterials.com/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Business Description Sheet http://advbiomaterials.com/role/BusinessDescription Business Description Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://advbiomaterials.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Interim Financial Statements and Basis of Presentation Sheet http://advbiomaterials.com/role/InterimFinancialStatementsAndBasisOfPresentation Interim Financial Statements and Basis of Presentation Notes 9 false false R10.htm 00000010 - Disclosure - Recent Accounting Pronouncements Sheet http://advbiomaterials.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations Sheet http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperations Held for Sale Assets and Liabilities and Discontinued Operations Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://advbiomaterials.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Income Per Share Sheet http://advbiomaterials.com/role/IncomePerShare Income Per Share Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes Sheet http://advbiomaterials.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - Promissory Notes Notes http://advbiomaterials.com/role/PromissoryNotes Promissory Notes Notes 15 false false R16.htm 00000016 - Disclosure - Long-Term Financing Obligation Sheet http://advbiomaterials.com/role/Long-termFinancingObligation Long-Term Financing Obligation Notes 16 false false R17.htm 00000017 - Disclosure - Stockholders' Deficit Sheet http://advbiomaterials.com/role/StockholdersDeficit Stockholders' Deficit Notes 17 false false R18.htm 00000018 - Disclosure - Stock-Based Compensation Sheet http://advbiomaterials.com/role/Stock-basedCompensation Stock-Based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Concentrations of Credit Risk and Major Customers Sheet http://advbiomaterials.com/role/ConcentrationsOfCreditRiskAndMajorCustomers Concentrations of Credit Risk and Major Customers Notes 19 false false R20.htm 00000020 - Disclosure - Legal Proceedings Sheet http://advbiomaterials.com/role/LegalProceedings Legal Proceedings Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Events Sheet http://advbiomaterials.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations (Tables) Sheet http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperationsTables Held for Sale Assets and Liabilities and Discontinued Operations (Tables) Tables http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperations 22 false false R23.htm 00000023 - Disclosure - Stock-Based Compensation (Tables) Sheet http://advbiomaterials.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://advbiomaterials.com/role/Stock-basedCompensation 23 false false R24.htm 00000024 - Disclosure - Business Description (Details Narrative) Sheet http://advbiomaterials.com/role/BusinessDescriptionDetailsNarrative Business Description (Details Narrative) Details http://advbiomaterials.com/role/BusinessDescription 24 false false R25.htm 00000025 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations (Details Narrative) Sheet http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperationsDetailsNarrative Held for Sale Assets and Liabilities and Discontinued Operations (Details Narrative) Details http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperationsTables 25 false false R26.htm 00000026 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Components of Assets Held-for-Sale (Details) Sheet http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperations-ScheduleOfComponentsOfAssetsHeld-for-saleDetails Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Components of Assets Held-for-Sale (Details) Details 26 false false R27.htm 00000027 - Disclosure - Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Discontinued Operations (Details) Sheet http://advbiomaterials.com/role/HeldForSaleAssetsAndLiabilitiesAndDiscontinuedOperations-ScheduleOfDiscontinuedOperationsDetails Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Discontinued Operations (Details) Details 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://advbiomaterials.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://advbiomaterials.com/role/RelatedPartyTransactions 28 false false R29.htm 00000029 - Disclosure - Income Per Share (Details Narrative) Sheet http://advbiomaterials.com/role/IncomePerShareDetailsNarrative Income Per Share (Details Narrative) Details http://advbiomaterials.com/role/IncomePerShare 29 false false R30.htm 00000030 - Disclosure - Income Taxes (Details Narrative) Sheet http://advbiomaterials.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://advbiomaterials.com/role/IncomeTaxes 30 false false R31.htm 00000031 - Disclosure - Promissory Notes (Details Narrative) Notes http://advbiomaterials.com/role/PromissoryNotesDetailsNarrative Promissory Notes (Details Narrative) Details http://advbiomaterials.com/role/PromissoryNotes 31 false false R32.htm 00000032 - Disclosure - Long-Term Financing Obligation (Details Narrative) Sheet http://advbiomaterials.com/role/Long-termFinancingObligationDetailsNarrative Long-Term Financing Obligation (Details Narrative) Details http://advbiomaterials.com/role/Long-termFinancingObligation 32 false false R33.htm 00000033 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://advbiomaterials.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://advbiomaterials.com/role/StockholdersDeficit 33 false false R34.htm 00000034 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://advbiomaterials.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://advbiomaterials.com/role/Stock-basedCompensationTables 34 false false R35.htm 00000035 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://advbiomaterials.com/role/Stock-basedCompensation-ScheduleOfStockOptionActivityDetails Stock-Based Compensation - Schedule of Stock Option Activity (Details) Details 35 false false R36.htm 00000036 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes Pricing Model Assumptions (Details) Sheet http://advbiomaterials.com/role/Stock-basedCompensation-ScheduleOfBlack-scholesPricingModelAssumptionsDetails Stock-Based Compensation - Schedule of Black-Scholes Pricing Model Assumptions (Details) Details 36 false false R37.htm 00000037 - Disclosure - Concentrations of Credit Risk and Major Customers (Details Narrative) Sheet http://advbiomaterials.com/role/ConcentrationsOfCreditRiskAndMajorCustomersDetailsNarrative Concentrations of Credit Risk and Major Customers (Details Narrative) Details http://advbiomaterials.com/role/ConcentrationsOfCreditRiskAndMajorCustomers 37 false false R38.htm 00000038 - Disclosure - Subsequent Events (Details Narrative) Sheet http://advbiomaterials.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://advbiomaterials.com/role/SubsequentEvents 38 false false All Reports Book All Reports asnb-20191231.xml asnb-20191231.xsd asnb-20191231_cal.xml asnb-20191231_def.xml asnb-20191231_lab.xml asnb-20191231_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 20 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events
 9 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events

15. Subsequent Events

 

We evaluated all events or transactions that occurred after the balance sheet date through the date when we filed these financial statements and, other than as discussed below, we determined that we did not have any other material recognizable subsequent events.

 

On November 25, 2019, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the “Asset Sale”). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020, we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.
XML 21 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Held for Sale Assets and Liabilities and Discontinued Operations (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 31, 2020
Nov. 25, 2019
Dec. 22, 2011
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2019
Inventories, net       $ 271   $ 271   $ 248
Financing obligation       1,986   1,986   1,986
Accrued interest on financing obligation       155   155   168
Liabilities held for sale       2,490   2,490   $ 2,536
Loss from continuing operations       $ 65 $ 54 $ 185 $ 152  
Asset Purchase Agreement [Member] | Independent Third-Party [Member]                
Inventory held for sale     $ 2,000          
Proceeds from land and building     1,986          
Accrued interest on financing obligation     2,141          
Liabilities held for sale     $ 2,154          
Asset Purchase Agreement [Member] | Subsequent Event [Member]                
Purchase price of asset $ 7,250              
Asset Purchase Agreement [Member] | Mitsubishi Chemical Performance Polymers, Inc [Member]                
Purchase price of asset   $ 7,250            
Asset Purchase Agreement [Member] | Mitsubishi Chemical Performance Polymers, Inc [Member] | Subsequent Event [Member]                
Purchase price of asset 1,150              
Transaction and legal costs 567              
Facility related obligations 483              
Contingent facility maintenance costs $ 100              
XML 22 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Income Per Share (Details Narrative) - shares
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]        
Potentially dilutive shares, excluded from the diluted income per share 410,000 1,220,008 410,000 1,137,025
XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 24 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2019
Mar. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 5 $ 5
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 28,339,063 28,339,063
Common stock, shares outstanding 28,262,371 28,262,371
Treasury stock shares 76,692 76,692
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Business Description
 9 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Business Description

1. Business Description

 

On January 31, 2020 (the “Closing Date”), we completed the sale of substantially all of our assets (the “Asset Sale”) for a total purchase price of $7,250,000 pursuant to an Asset Purchase Agreement entered into between us and Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”). Prior to the Closing Date, we developed and manufactured advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials were marketed and sold to medical device manufacturers who used our advanced polymers in devices designed for treating a broad range of anatomical sites and disease states.

 

As a result of the Asset Sale, we ceased operating as a developer, manufacturer, marketer and seller of advanced polymers. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. As our efforts in engaging with an operating company subsequent to the Closing Date has not yet commenced, our activities are subject to significant risks and uncertainties, including the need to raise additional capital if we are unable to identify an operating company desiring to acquire or merge with us.

 

Prior to the Closing Date, our corporate, development and manufacturing operations were located in a leased facility in Wilmington, Massachusetts.
XML 26 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 05, 2019
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Dec. 05, 2016
Apr. 26, 2016
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2019
Number of stock options shares granted   200,000 750,000 5,600,000              
Carroll Note [Member]                      
Interest expense             $ 0 $ 1 $ 1 $ 2  
Affiliate Notes [Member]                      
Interest expense             4 4 10 10  
Affiliate Notes [Member] | 2017 Non-Qualified Equity Incentive Plan [Member]                      
Note principal balance outstanding $ 125                    
Number of stock options shares granted 2,083,333                    
Purchase price upon exercise of stock options $ 125                    
Khristine Carroll [Member] | Carroll Note [Member]                      
Issuance of promissory note           $ 25          
Note due date description           The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016.          
Note interest rate           10.00%          
Repayments of promissory note               15 5  
Note principal balance outstanding                     $ 15
Michael Adams [Member] | First Affiliate Note [Member]                      
Issuance of promissory note           $ 25          
Note due date description           The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016.          
Note interest rate           10.00%          
Repayments of promissory note                  
Note principal balance outstanding             0   0   25
Michael Adams [Member] | Second Affiliate Note [Member]                      
Issuance of promissory note         $ 100            
Note due date description         The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017.            
Note interest rate         12.00%            
Repayments of promissory note                  
Note principal balance outstanding             $ 0   $ 0   $ 100
Commitment fee         $ 3            
XML 27 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Legal Proceedings
 9 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings

14. Legal Proceedings

 

We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.
XML 28 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Business Description (Details Narrative)
$ in Thousands
Jan. 31, 2020
USD ($)
Subsequent Event [Member] | Asset Purchase Agreement [Member]  
Purchase price of asset $ 7,250
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions
 9 Months Ended
Dec. 31, 2019
Related Party Transactions [Abstract]  
Related Party Transactions

6. Related Party Transactions

 

On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the “Carroll Note”). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.

 

On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the “Affiliate”) in the principal amount of $25,000 (the “First Affiliate Note”). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.

 

On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the “Second Affiliate Note”). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.

 

As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the “Affiliate Notes”) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the “2017 Option Plan”). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.

 

During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Long-Term Financing Obligation
 9 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Long-Term Financing Obligation

10. Long-Term Financing Obligation

 

On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. In addition, we provided, as collateral, a security interest in all furnishings, fixtures and equipment owned and used by us, having a net book value of approximately $0 as of December 31, 2019. For accounting purposes, the provision of such collateral constitutes continuing involvement with the associated property. Due to this continuing involvement, this sale-leaseback transaction is accounted for under the financing method, rather than as a completed sale. Under the financing method, we include the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. Through December 2018, interest on the financing obligation exceeded the minimum lease payments, accordingly the principal remains constant through that date. After December 2018, the minimum lease payment will exceed interest and principal will be reduced by the excess of minimum lease payment over interest. The building, building improvements and land remain on the condensed balance sheet and the building and building improvements will continue to be depreciated over their remaining useful lives. Payments made under the lease are applied as payments of imputed interest and deemed principal on the underlying financing obligation.

 

In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (“MCPP”), which was completed on January 31, 2020 (the “Closing Date”), our lease with the independent third-party owner of the building was assigned to MCPP. As a result, subsequent to the Closing Date, we have no further obligations with respect to the lease agreement.
XML 31 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]        
Number of Options Outstanding Beginning Balance       1,788,750
Number of Options Granted      
Number of Options Exercised       (656,250)
Number of Options Cancelled or Forfeited       (722,500)
Number of Options Outstanding Ending Balance       410,000
Number of Options Exercisable       410,000
Number of Options Vested or Expected to Vest       410,000
Weighted-average Exercise Price Per Share Outstanding Beginning Balance       $ 0.20
Weighted-average Exercise Price Per Share Granted $ 0.060 $ 0.040 $ 0.06  
Weighted-average Exercise Price Per Share Cancelled or Forfeited       0.29
Weighted-average Exercise Price Per Share Outstanding Ending Balance       0.27
Weighted-average Exercise Price Per Share Exercisable       0.27
Weighted-average Exercise Price Per Share Vested or Expected to Vest       $ 0.27
Weighted-average Remaining Contractual Term in Years Outstanding, Beginning       2 years 11 days
Weighted-average Remaining Contractual Term in Years Outstanding, Ending       2 months 23 days
Weighted-average Remaining Contractual Term in Years Exercisable       2 months 23 days
Weighted-average Remaining Contractual Term in Years Vested or Expected to Vest       2 months 23 days
Aggregate Intrinsic Value Outstanding Beginning       $ 20
Aggregate Intrinsic Value Outstanding Ending       1
Aggregate Intrinsic Value Exercisable       1
Aggregate Intrinsic Value, Vested or Expected to Vest       $ 1
XML 32 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 05, 2019
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Dec. 05, 2016
Apr. 26, 2016
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2019
Number of stock options shares granted   200,000 750,000 5,600,000              
Carroll Note [Member]                      
Interest expense             $ 0 $ 1 $ 1 $ 2  
Affiliate Notes [Member]                      
Interest expense             4 4 10 10  
Affiliate Notes [Member] | 2017 Non-Qualified Equity Incentive Plan [Member]                      
Note principal balance outstanding $ 125                    
Number of stock options shares granted 2,083,333                    
Purchase price upon exercise of stock options $ 125                    
Khristine Carroll [Member] | Carroll Note [Member]                      
Issuance of promissory note           $ 25          
Note due date description           The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016.          
Note interest rate           10.00%          
Repayments of promissory note               15 5  
Note principal balance outstanding                     $ 15
Michael Adams [Member] | First Affiliate Note [Member]                      
Issuance of promissory note           $ 25          
Note due date description           The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016.          
Note interest rate           10.00%          
Repayments of promissory note                  
Note principal balance outstanding             0   0   25
Michael Adams [Member] | Second Affiliate Note [Member]                      
Issuance of promissory note         $ 100            
Note due date description         The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017.            
Note interest rate         12.00%            
Repayments of promissory note                  
Note principal balance outstanding             $ 0   $ 0   $ 100
Commitment fee         $ 3            
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Held for Sale Assets and Liabilities and Discontinued Operations (Tables)
 9 Months Ended
Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Components of Assets Held-for-Sale

 

Assets of Discontinued Operations Held for Sale   December 31, 2019     March 31, 2019  
(in thousands)                
Inventories, net   $ 271     $ 248  
Property, plant and equipment, net     1,749       1,791  
Deferred financing costs, net     47       52  
Assets of discontinued operations held for sale   $ 2,067     $ 2,091  

 

(in thousands)   December 31, 2019     March 31, 2019
           
Raw materials   $ 129     $ 121
Work in progress     35       48
Finished goods     107       79
Total inventories, net   $ 271     $ 248

 

(in thousands)   December 31, 2019     March 31, 2019  
             
Land   $ 500     $ 500  
Building     2,705       2,705  
Machinery, equipment and tooling     1,248       1,248  
Furniture, fixtures and office equipment     285       285  
Office equipment under capital lease     13       13  
      4,752       4,751  
Less: accumulated depreciation     (3,003 )     (2,960 )
Property, plant and equipment, net   $ 1,749     $ 1,791  
Schedule of Discontinued Operations

Accordingly, the results of our operations are reported as discontinued operations for all periods are presented below.

 

Results of Discontinued Operations   For the Three Months Ended December 31, 2019     For the Three Months Ended December 31, 2018     For the Nine Months Ended December 31, 2019     For the Nine Months Ended December 31, 2018  
(in thousands)                                
Revenues:                                
Product sales   $ 457     $ 608     $ 1,632     $ 1,564  
License and royalty fees     351       281       803       708  
Total revenues     808       889       2,435       2,272  
Cost of sales     194       259       641       670  
Gross profit     614       630       1,794       1,602  
Operating expenses:                                
Research, development and regulatory     103       77       280       253  
Selling, general and administrative     495       271       1,049       847  
Total operating expenses     598       348       1,329       1,100  
Income (loss) from discontinued operations     16       282       465       502  
Other income (expense) from discontinued operations, net:                                
Gain on disposition of sales-leaseback assets     34       382       34       382  
Interest expense     (136 )     (94 )     (370 )     (282 )
Other income (expense) from discontinued operations, net     (102 )     288       (336 )     100  
Income (loss) from discontinued operations before provision for income taxes     (86 )     570       129       602  
Provision for income taxes     -       -       -       -  
Net income (loss) from discontinued operations   $ (86 )   $ 570     $ 129     $ 602  
                                 
Net income (loss) from discontinued operations per common share:                                
Basic   $ (0.00 )   $ 0.03     $ 0.01     $ 0.03  
Diluted     (0.00 )     0.03       0.01       0.03  
                                 
Shares used in computing net income from discontinued operations per common share:                                
Basic     23,498       21,491       22,157       21,491  
Diluted     23,498       22,711       22,157       22,627  
XML 34 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Components of Assets Held-for-Sale (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Mar. 31, 2019
Inventories, net $ 271 $ 248
Property, plant and equipment, net 1,749 1,791
Deferred financing costs, net 47 52
Assets of discontinued operations held for sale 2,067 2,091
Property, plant and equipment, gross 4,752 4,751
Less: accumulated depreciation (3,003) (2,960)
Land [Member]    
Property, plant and equipment, gross 500 500
Building [Member]    
Property, plant and equipment, gross 2,705 2,705
Machinery, Equipment and Tooling [Member]    
Property, plant and equipment, gross 1,248 1,248
Furniture, Fixtures and Office Equipment [Member]    
Property, plant and equipment, gross 285 285
Office Equipment Under Capital Lease [Member]    
Property, plant and equipment, gross 13 13
Raw Materials [Member]    
Inventories, net 129 121
Work in Progress [Member]    
Inventories, net 35 48
Finished Goods [Member]    
Inventories, net $ 107 $ 79
XML 35 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Interim Financial Statements and Basis of Presentation
 9 Months Ended
Dec. 31, 2019
Interim Financial Statements And Basis Of Presentation  
Interim Financial Statements and Basis of Presentation

3. Interim Financial Statements and Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three and nine months ended December 31, 2019 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The information contained in this quarterly report on Form 10-Q should be read in conjunction with our audited financial statements included in our annual report on Form 10-K, as of and for the year ended March 31, 2019 as filed with the Securities and Exchange Commission (the “SEC”).

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments, which are evaluated on an ongoing basis, and that affect the amounts reported in our unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to revenue recognition, allowance for doubtful accounts, inventory reserves, useful lives and valuation of property and equipment.

 

Our significant accounting policies are described in Note 3 to the audited financial statements as of March 31, 2019 which are included in our Annual Report on Form 10-K as filed with the SEC on August 23, 2019.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. these reclassifications had no effect on the previously reported financial position or results of operations.
XML 36 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
 9 Months Ended
Dec. 31, 2019
Apr. 01, 2020
Cover [Abstract]    
Entity Registrant Name AdvanSource Biomaterials Corp  
Entity Central Index Key 0001011060  
Document Type 10-Q  
Document Period End Date Dec. 31, 2019  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   28,262,371
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2020  
XML 37 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Statement of Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Treasury Stock [Member]
Total
Balance at Mar. 31, 2018 $ 21 $ 38,404 $ (39,280) $ (30) $ (885)
Balance, shares at Mar. 31, 2018 21,491,000        
Net income (loss) (91) (91)
Balance at Jun. 30, 2018 $ 21 38,404 (39,371) (30) (976)
Balance, shares at Jun. 30, 2018 21,491,000        
Balance at Mar. 31, 2018 $ 21 38,404 (39,280) (30) (885)
Balance, shares at Mar. 31, 2018 21,491,000        
Net income (loss)           450
Balance at Dec. 31, 2018 $ 21 38,423 (38,830) (30) (416)
Balance, shares at Dec. 31, 2018 21,491,000        
Balance at Jun. 30, 2018 $ 21 38,404 (39,371) (30) (976)
Balance, shares at Jun. 30, 2018 21,491,000        
Net income (loss) 25 25
Stock-based compensation 19 19
Balance at Sep. 30, 2018 $ 21 38,423 (39,346) (30) (932)
Balance, shares at Sep. 30, 2018 21,491,000        
Net income (loss) 516 516
Balance at Dec. 31, 2018 $ 21 38,423 (38,830) (30) (416)
Balance, shares at Dec. 31, 2018 21,491,000        
Balance at Mar. 31, 2019 $ 21 38,427 (38,946) (30) (528)
Balance, shares at Mar. 31, 2019 21,491,000        
Net income (loss) 83 83
Balance at Jun. 30, 2019 $ 21 38,427 (38,863) (30) (445)
Balance, shares at Jun. 30, 2019 21,491,000        
Balance at Mar. 31, 2019 $ 21 38,427 (38,946) (30) (528)
Balance, shares at Mar. 31, 2019 21,491,000        
Net income (loss)           (56)
Balance at Dec. 31, 2019 $ 28 38,610 (39,002) (30) (394)
Balance, shares at Dec. 31, 2019 28,262,000        
Balance at Jun. 30, 2019 $ 21 38,427 (38,863) (30) (445)
Balance, shares at Jun. 30, 2019 21,491,000        
Net income (loss) 12 12
Balance at Sep. 30, 2019 $ 21 38,427 (38,851) (30) (433)
Balance, shares at Sep. 30, 2019 21,491,000        
Net income (loss) (151) (151)
Common stock issued on exercise of stock options $ 6 159 165
Common stock issued on exercise of stock options, shares 5,941,000        
Common stock on exercise of warrants $ 1 24 25
Common stock on exercise of warrants, shares 830,000        
Balance at Dec. 31, 2019 $ 28 $ 38,610 $ (39,002) $ (30) $ (394)
Balance, shares at Dec. 31, 2019 28,262,000        
XML 38 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Concentrations of Credit Risk and Major Customers (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2019
Accounts receivable-trade $ 213   $ 213   $ 483
Two Customers [Member]          
Concentrations of credit risk percentage     47.00%    
Accounts receivable-trade 100   $ 100    
Due from customer $ 343   $ 343   $ 185
One Customers [Member]          
Concentrations of credit risk percentage         13.00%
Accounts receivable-trade         $ 61
Revenue [Member] | Two Customers [Member]          
Concentrations of credit risk percentage 49.00%        
Revenue [Member] | Three Customers [Member]          
Concentrations of credit risk percentage   66.00% 52.00% 53.00%  
XML 39 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Deficit (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 16 Months Ended
Dec. 05, 2019
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Jul. 22, 2015
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 13, 2018
Nov. 27, 2019
Number of shares exercised options to purchase   200,000 750,000 5,600,000            
Option exercise price   $ 0.060 $ 0.040 $ 0.06            
2017 Non-Qualified Equity Incentive Plan [Member] | Michael Adams [Member]                    
Number of shares exercised options to purchase       2,500,000            
Option exercise price       $ 0.06            
Common Stock Warrants [Member] | Advisor [Member]                    
Compensate amount         $ 4          
Number of warrant purchase shares of common stock         830,500         830,500
Warrant exercise price         $ 0.03          
Warrant, value         $ 28          
Common stock in consideration cash                   $ 25
Common Stock Options [Member]                    
Number of shares exercised options to purchase 4,050,000            
Number of shares cashless exercise of common stock 2,910,000                  
Common Stock Options [Member] | Michael Adams [Member]                    
Number of shares exercised options to purchase 2,083,333                  
Principal balance due on Affiliate Notes $ 125                  
Options remaining exercisable shares 416,667                  
Number of shares cashless exercise of common stock 291,667                  
Common Stock Options [Member] | 2017 Non-Qualified Equity Incentive Plan [Member] | Michael Adams [Member]                    
Number of shares exercised options to purchase       2,500,000            
Option exercise price       $ 0.06            
Common Stock Options [Member] | Directors and Certain Employees [Member] | 2003 Stock Option Plan [Member]                    
Common stock in consideration cash $ 40                  
Number of shares exercised options to purchase 656,250                  
Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member] | Minimum [Member]                    
Option exercise price                 $ 0.04  
Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member] | Maximum [Member]                    
Option exercise price                 $ 0.06  
Common Stock Options [Member] | Directors, Certain Employees and One Consultant [Member] | 2017 Non-Qualified Equity Incentive Plan [Member]                    
Number of shares exercised options to purchase                 4,050,000  
XML 40 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Recent Accounting Pronouncements
 9 Months Ended
Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Recent Accounting Pronouncements

4. Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on our accounting and reporting. We believe that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on our accounting or reporting or that such impact will not be material to our financial position, results of operations and cash flows when implemented.

 

Recent accounting pronouncements are included in Note 3 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2019.
XML 41 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
 9 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes

8. Income Taxes

 

We are required to file federal and state income tax returns in the United States. The preparation of these tax returns requires us to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by us. In consultation with our tax advisors, we base our tax returns on interpretations that are believed to be reasonable under the circumstances. The tax returns, however, are subject to routine reviews by the various federal and state taxing authorities in the jurisdictions in which we file tax returns. As part of these reviews, a taxing authority may disagree with respect to the income tax positions taken by us (“uncertain tax positions”) and, therefore, may require us to pay additional taxes. As required under applicable accounting rules, we accrue an amount for our estimate of additional income tax liability, including interest and penalties, which we could incur as a result of the ultimate or effective resolution of the uncertain tax positions. We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

 

We had no income tax credits for the three and nine months ended December 31, 2019 and 2018. The effective tax rates for the three and nine months ended December 31, 2019 was 21.0%. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.

 

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.
XML 42 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation
 9 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

12. Stock-Based Compensation

 

In October 2003, our shareholders approved the AdvanSource 2003 Stock Option Plan (the “2003 Plan”), which authorizes the issuance of 3,000,000 shares of common stock. Under the terms of the Plan, the exercise price of Incentive Stock Options issued under the Plan must be equal to the fair market value of the common stock at the date of grant. In the event that Non-Qualified Options are granted under the Plan, the exercise price may be less than the fair market value of the common stock at the time of the grant (but not less than par value). Total shares of common stock registered under the 2003 Plan are 7,000,000 shares. Normally, options granted expire ten years from the grant date.

 

Activity under the 2003 Plan for the nine months ended December 31, 2019 is as follows:

 

    Number of Options     Weighted-Average Exercise Price per Share     Weighted-
Average Remaining Contractual
Term in Years		     Aggregate Intrinsic Value (in thousands)  
Options outstanding as of April 1, 2019     1,788,750     $ 0.20       2.03     $ 20  
Granted     -                          
Exercised     (656,250 )                        
Cancelled or forfeited     (722,500 )   $ 0.29                  
Options outstanding as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  
Options exercisable as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  
Options vested or expected to vest as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on December 31, 2019 of $0.165 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on December 31, 2019.

 

On December 5, 2019, our directors and certain employees exercised options to purchase 656,250 shares of our common stock pursuant to grants made under the 2003 Plan. In consideration for the exercise of these options we received approximately $40,000 in cash. There were no stock options exercised under the 2003 Plan for the three and nine months ended December 31, 2018. As of December 31, 2019, there were no shares remaining to be granted under the 2003 Plan.

 

For the three and nine months ended December 31, 2019 and 2018, we recorded no stock-based compensation expense for options pursuant to the 2003 Plan. As of December 31, 2019, we had no unrecognized compensation cost related to stock options.

 

On August 14, 2017, our board of directors approved and adopted the 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”), which authorized the grant of non-qualified stock options exercisable into a maximum of 7,000,000 shares of our common stock. Under the terms of the 2017 Plan, the exercise price of stock options issued under the 2017 Plan must be equal to the fair market value of the common stock at the date of grant. Options granted expire ten years from the grant date. From August 17, 2017 through December 13, 2018, the board of directors approved the grant of stock options to certain directors, employees and a consultant which were immediately vested and exercisable into a total of 6,550,000 shares of our common stock. There were no additional stock options granted pursuant to the 2017 Plan for the period subsequent to December 31, 2018. In determining the fair value of the options granted pursuant to the 2017 Plan, we utilized the Black-Scholes pricing model utilizing the following assumptions:

 

    August 17, 2017 Option Grants     August 16, 2018 Option Grants     December 13, 2018 Option Grants  
Total shares granted     5,600,000       750,000       200,000  
Option exercise price per share   $ 0.06     $ 0.040     $ 0.060  
Grant date fair market value per share   $ 0.06     $ 0.046     $ 0.059  
Expected term of option in years     10.0       2.00       1.00  
Expected volatility     100 %     100 %     100 %
Expected dividend rate     0.00 %     0.00 %     0.00 %
Risk free interest rate     1.00 %     0.00 %     2.69 %

 

On August 17, 2017, Michael Adams, our chief executive officer, was granted an option to purchase 2,500,000 shares of our common stock (the “Adams Option”) at an exercise price of $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, Mr. Adams effected a partial exercise of the Adams Option and purchased 2,083,333 shares of our common stock. As consideration for the exercise of a portion of the Adams Option, an affiliate of Mr. Adams authorized that the principal balance due on the Affiliate Notes, previously described in Notes 6 and 11, in the aggregate amount of $125,000, be used for purposes of exercising this portion of the Adams Option. Additionally, on December 5, 2019, Mr. Adams exercised the remaining 416,667 shares exercisable pursuant to the Adams Option, by means of a cashless exercise. As a result of the cashless exercise, Mr. Adams was issued 291,667 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

  

On various dates from August 17, 2017 through December 13, 2018, our directors, certain employees and one consultant (the “Grantees”) were granted options to purchase 4,050,000 shares of our common stock at exercise prices ranging from $0.04 per share to $0.06 per share pursuant to the 2017 Plan. On December 5, 2019, the Grantees exercised their options to purchase 4,050,000 shares of our common stock, by means of a cashless exercise. As a result of the cashless exercise, the Grantees were issued 2,910,000 shares of our common stock. We received no cash proceeds in connection with this cashless exercise.

 

As of December 31, 2019, there were 450,000 shares available to grant pursuant to the 2017 Plan and no options outstanding or exercisable.
XML 43 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation - Schedule of Black-Scholes Pricing Model Assumptions (Details) - $ / shares
Dec. 13, 2018
Aug. 16, 2018
Aug. 17, 2017
Share-based Payment Arrangement [Abstract]      
Total shares granted 200,000 750,000 5,600,000
Option exercise price per share $ 0.060 $ 0.040 $ 0.06
Grant date fair market value per share $ 0.059 $ 0.046 $ 0.06
Expected term of option in years 1 year 2 years 10 years
Expected volatility 100.00% 100.00% 100.00%
Expected dividend rate 0.00% 0.00% 0.00%
Risk free interest rate 2.69% 0.00% 1.00%
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Long-Term Financing Obligation (Details Narrative) - USD ($)
$ in Thousands
Dec. 22, 2011
Dec. 31, 2019
Mar. 31, 2019
Debt Disclosure [Abstract]      
Proceeds of sale of land and building $ 2,000    
Initial minimum lease term Pursuant to a lease agreement, the initial minimum lease term is 15 years.    
Lease back description At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each.    
Fixtures and equipment net book value   $ 0  
Financing obligation   1,986 $ 1,986
Accrued interest on financing obligation   $ 155 $ 168
EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $>(@5 ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 1XB!4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !'B(%0D=$!=.X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2@,Q$(9?17+?G61;%,(VEXHG!<&"XBTDTS:XV0W)R&[?WFQL MMX@^@,?,_/GF&YC6!&F&B,]Q"!C)8;J9?-NPI@:@%,#5/#*>I:^$*F&&$T:?O MJ%6*I_8DL'V#DY);>DQG&LQU7)Y1T$ MO#T]OI1U*] &W:9_+K:WN\>F&IXPRN^KKC8B3O)A6S6[[/K M#[^KL!^LV[M_;'P15"W\N@OU!5!+ P04 " !'B(%0F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( $>(@5#KTE^-B@( *8) 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q U;S M?ANB\'WBI;J5RDQ$1=[1&_O&U/?N*/0HFJQOT6@X:1KBO/]N M_:-U7CMSHI(=>/VSNJAR&V9A<&%7>J_5"^\_L=&A51B,WG]A#U9KN%F)UCCS M6MIO<+Y+Q9O1BEY*0]^&MFIMVP]_$C328 (>"7@BD/B_!#(2R$1 B75^6)EU M]0-5M,@%[P,Q1*NCYE"@9Z(W\VPF[=[9?]I;J6^S1\;\"!Q]!8 $">D LGDL, *%%AY M]+4CX",R6" %!5*/OG$$? 2*884UJ+#V^@-* M;'R^&VH LA!K%,/I%/L6W'!#F(6 HX6D1;X%-^809DD%S-P=PIX%[%T. &;A M>D!P^B+B6\"N"H!9N",0G.7(3V*_=[9 M/+$S/YOZI3EHW7IO95$U"__0ML>'(&@V!UUFS;TYZLI^LS-UF;6V6>^#YECK M;-L'E44 81@'9997_G+>/WNLEW-S:HN\TH^UUYS*,JO_K'1AS@M?^.\/GO+] MH>T>!,OY,=OK[[K]<7RL;2NX]K+-2UTUN:F\6N\6_@?QL(99%] K?N;ZW(SN MO2Z59V->NL:7[<(/.T>ZT)NVZR*SEU>]UD71]61]_!XZ]:]C=H'C^_?>/_7) MVV2>LT:O3?$KW[:'A9_XWE;OLE/1/IGS9STDI'QOR/ZK?M6%E7=.[!@;4S3] MI[A_[?P_@ & +@&B#DS8!H"(A00'!QUJ?Z,6NS MY;PV9Z^^S-8QZQ:%>(AL,3?=P[YV_7R#:D2B>!\QZR.F/E#- M5S&M1QCCB>%$J>"=S%@G,^HD04YF-%LR,U3CF)>$=9%0%RERD= 11()M4!&D MHQ4_<9*R3E+B1(;(24I7(9Z7FY*)"Q'R] FI#X*?D)8$HA CB*H@31QK1#A8 M* B'I./]%SS(!-!\(IP/T*JEN+*<*';5EH>BH%24F(J#9C*,C+$7*HJ<=>'! M*"@9)2:CH-@3J&'XZ%K[@V2@H'''&*T')!S(E2XY1J1%HIVYX0@J*2/R6 MK3A-@KU01(K1&SVUPB-24$9*3"?! # &B, MRNV&QZ6@O%2$4PQ3R33=U$QW2CPQ(22,4JZ]%D\Y$#07S"A&0W*YK9DZ<6S[ M*"T5)A10$ )QPF@>E4!9J3"?@,%@$@M,!58FP<%NX'D)E)<*0PHH"N^B M- SQYIS5):ET@ IX; +%IL*@ @K$._)#_1_1U L/3:! 5'@W!Q2(MCJ8#9Q* M@6L5\]P$RDV%N3EHQD<+9@_#J)@]3# ZVG5G[6]9O<^KQGLVK3TE]F>YG3&M MMCV&]S:S@SW>7QN%WK7=[UYBH3$WM00!BKT%5ZQ:Y&MO1(B<77E2OMCZ4!J5XJ7#/9FU'EK(G MY%5VOAW7+I!$N,8'+D,@<;GB+:YK&4EP_!F#NE-.:9RWWZ-_4<6+8O:(X2VI M?U='7J[=U'6.^(0N-7\F_5<\%A2YSEC]=WS%M9!+$I'C0&JF_IW#A7'2C%$$ M2H/>AFO5JFL_W(GBT68WP-$ )X,?WC0$HR'0#-Y IDK]C#@J5<89)9M! F<2N%1L347P7^*)_!,$M$) MY0_F$+[='UC]@?*'<[^&N!DDL9*T2A)I1=Q2+!A"*T-H,@0:PR!)9AG $P"^ MQG%/M6")K"R1R1)J+(,DFE<+U$^CN:];\,16GMCDT69_8TK"5$.Y*5E0)%:* MQ*2(-0I38E#;.#Q9L>*/.=_('JN6N;L"1#-WW %/\ 4$L#!!0 ( $>(@5#S M$*QLE0, "\1 8 >&PO=V]R:W-H965T&ULC9A1CZ(Z M%(#_"N%]!UHHH%&3$;FY-[F;3'9S[SXS6I4,4!?J./OOMT#'A9ZC]66$SG=. M^[650UU<1//6'CF7SD=5UNW2/4IYFGM>NSWR*F^?Q(G7ZC][T52Y5+?-P6M/ M#<]W?5!5>M3W(Z_*B]I=+?JVEV:U$&=9%C5_:9SV7%5Y\VO-2W%9NL3];/A6 M'(ZR:_!6BU-^X-^Y_._TTJ@[[YIE5U2\;@M1.PW?+]UG,L^HWP7TQ/\%O[2C M:Z=3>17BK;OY9[=T_6Y$O.1;V:7(U<<[3WE9=IG4.'[JI.ZUSRYP?/V9_:]> M7LF\YBU/1?FCV,GCTDU<9\?W^;F4W\3E;ZZ%F.MH^W_Y.R\5WHU$];$59=O_ M=;;G5HI*9U%#J?*/X;.H^\^+SO\9A@=0'4"O :KO>P&!#@C^!(1W T(=$#[: M ],!S.C!&]S[R=SD,E\M&G%QFF$_G/)NVY$Y4\NU[1K[U>G_I^:S5:WOJY@N MO/X?$A&A_V\>$X/C+F>D"B'JE[Y$O$C+E &&9.!L*0Q$B481"CN!%# MC1@TB@VC 6%WC1 &&"$,-,*@6T81:A1!H\0P@DAH(*D=V=B1["XR<8E1EQBZ MS R7^('501BP.@@#5P>#;JU.@AHEP"CQ#:,$=I(8W[(4,BPV\FP@0Z@Q>QED M(O^&SPSUF4$?8OC,L"^I :408L20WB")F,%DD F9CPL1'Z\G/GA()C>FA-RH M2 1.BE%OUIH9#]18OU0CR=C7?_*-F=L\AF56;&J&EKEG0J%9:)I1L*> V8#, MQLB3#THRI% Q2[*I%UX720"]F.D5/#*<%,$414VWP#9)F2W1U NOUR2$>SFZ MD0&OCP062+B78=$"*VY%-AJQ+K<-FUKA-9+ P@3W<62WBA[:QY!"Q2S)IEYX MO22P8";FZXQF+,^+%,&P?1S;'F.9+='4"Z^:)('[^,:+!,'K%$$*E?DJH9GQ MBM,@G)FO1AA&PAEX+B,8)2PVI\>6;7KZP&L6]8'=S'RMT(S-#L-H3$P[%(-V M*!;1V+#S1H>]BC>'_N3=.EMQKF6W[*/6Z^G^F7:'1:-]3>8I0=HW9)X-9_<_ MZ8>?$K[FS:&H6^=52'5$[0^2>R$D5Z/WG]2XCSS?76]*OI?=9:RNF^$(/]Q( M<=(_3WC7WTA6OP%02P,$% @ 1XB!4&A4@9 '!@ ^2< !@ !X;"]W M;W)K[$UIIS\..R/ MQ=UT6Y:GV]FL>-J:0UI\R4[F6/WE.OAD.;_W9M]]GXW%=.?'WS;O6S+^H/98GY* M7\R?IOSK]#6OWLTNO6QV!W,L=MEQDIOGN^DOXC;1LF[0$'_OS'OQZ?6D/I7' M+/M>O_EM;>3#[?=U3-8Y_VTZGEV/6#3^__MG[NCGY MZF0>T\(\9/M_=IMR>S>-II.->4Y?]^6W[/U7TYZ0/YVT9_^[>3/["J]'4AWC M*=L7S<_)TVM19H>VEVHHA_3'^??NV/Q^/_\EE&TSWD"V#>2E@?0'&ZBV@?IH M,'P$W3;0EP8J&&S@MPW\CR/$@PV"MD'PT4 /-@C;!N&E0=3,WSG<9K:6:9DN MYGGV/LG/!7=*Z[H6MV%5#T_UA\WT-W^K)JRH/GU;Q&(^>ZO[:9'[,R(_([*+ M/!!$=9$E070761'$[R)K@@1=)"%(>$%F51B71"1-1#;M]>?VD94((MI"'LY( MT"#'!I%6KDM$5*0].Q2D;E0L(\\*AF$6DQ FBGR>C:+9*,PFMK)!!+(Y(WXG M&QT+S_/X6#0=BX8#17;E(@)C&4>6X\A*PQG=V)?1>KR;9+B;3B8^S<2'8PC/ MJH)[9" 4?[QX?1@J*UZDJN)5H1T-P^SB)4P*4WK'GM/(#CGEADLB):Q*D):]^L5P6Y4%-G3O::<71,, MTJ+GZA4]IB)(2,H."2$,25Q9&8*+@D -P-660#@@!UEHF;'KF&!TQ:4M=6B9X4L=#8,N MT(C5E[H.[(08!YT+B2B-06(07V"$Y6(U A1BYU+E'"+0$O-0=3,*! M63HP*X%*X@N8KO&.DI&.NMEPKQ$H-D0Y$,)P8H>*1D6B%8T85P[&0443J%D'HV<)B7P1:.RQX.^L_(K'$'DJ@WL X1!LR"U.M0@$DQ#BH9P)IW>-E MDGN9)%XF[/\S"(0AH0>-U#.W(+&[[MGXM#<;%03"Q@ M:]]!+)2#6"@WL2 878@I9\\:@WH78L7%0A&Q@(680!C2M6*A>KZ.<1 +PN!X M',3"@5DI% *[JM<._23#_723X6*AB%@(V]P)A-$XB(5R$PN"U?7LVWMSE(-Z M9F*A>NQ+<;%03"SL#1\"84C7BH7B8J'0&;">';S"@5DZ,"M%/$#@?(WWE(SU MU$V'&X4B1B'L32@"83SXM5%@IX/2(7Q[?\[A6&L')F$'"_J69BXW"N5&V%LK M]P3";,C62JP'*IE;D&(69"LR@7 \:$&P_*"02/M[ 8=#K1V8A!VK9Z8T5Q_- MU,?V8@+A-_>H/I'R^A\BX.*CB?B KA((AT/$!YXD0(;I*L&HKE+.OE'PSGIT M57/QT4Q\;%TE$(9$Q(?KZNS3 TSU0W%_I/G+[EA,'K.RS [-$TO/65::JE?O M2]7?UJ2;RYN]>2[KEV'U.C\_C'9^4V:G]D&[V>5IO\7_4$L#!!0 ( $>( M@5#-[/M_A0, ,L/ 8 >&PO=V]R:W-H965T&UL?9?; MCMHP$(9?)\-Y"8 MW^-_?/CP+*^J?FY.4FKOM2RJ9N6?M#[?!T&S.\DR:^[465;FEX.JRTR;U_H8 M-.=:9ONN4UD$&(9)4&9YY:^77=MCO5ZJBR[R2C[67G,IRZS^MY&%NJY\\-\: M?N3'DVX;@O7RG!WE3ZE_G1]K\Q:,4?9Y*:LF5Y57R\/*?X#[+:9MAT[Q.Y?7 M9O+LM:D\*?77AZR2Z%_J.L7.204^]Z0_3?Y(@LC;YV8,7:J M:+I/;W=IM"J'*,9*F;WVWWG5?5^'^&_=^ XX=,"Q@QG[HPYBZ"#>.T1=\KVS M+M5/F<[6RUI=O;I?K7/6;@JX%V8R=VUC-W?=;R;;QK2^K $6R^"E#31H-KT& MIYI1$9CHXQ#(#;%!TAUO!]A211KQ(P@V"='U%U.#&/(!(C9 U 6(I@;L2>@E M22>I.LD,YK&5"">*D7<2LTYBX@00+"N])IZ, FC9W5)-$CJ,)*R1A)E31X"4 M#9#23,+(RH1JHKF52$J37? VYJR-.9.'X ,LV +9D7L/!;$)*:AE0C5S% X MMCF$_&$-B1>1V( M &D$87M!XD40)U0S<^PVX%$$@CJQ=\N@N9E\^VAL&=$,7;/"4PTHUJ+8]A)1 M+TEJ>Z&B6>0 +/!< PYLQ Q#-B!;EXIF EQ[EX<;)(P;DR(R)%0:K+BL\,)$"$P3:5B@- M,;7W'".:N?Y)D&3$JB4];&K%AMOIRZ5;HN-2>M8D3Y@6T)9[1M3J?9UY7N8OLS]GM7'O&J\ M)Z5-@=:540>EM#0>PSNS=B=368\OA3SH]C$USW5?7O8O6IV'TCD8Z_?U?U!+ M P04 " !'B(%0.V;%.K4! #2 P & 'AL+W=O3V!T%.)4_SF>.1= M[X*#5,7 .O@&[OMP-MXB*TO#)2C+M4(&VA+?I<=3'N)CP \.D]V<4:CDHO53 M,+XT)4Z"(!!0N\# _':%>Q B$'D9SPLG7E,&X/;\QOXIUNYKN3 +]UK\Y(WK M2WS J(&6C<(]ZNDS+/6\PV@I_BM<0?CPH,3GJ+6P<47U:)V6"XN7(MG+O',5 M]VF^R=(%M@^@"X"N@$/,0^9$4?E'YEA5&#TA,_=^8.&)TR/UO:F#,[8BWGGQ MUGNO59H="G(-1$O,:8ZAVY@U@GCV-07=2W&B_\#I/CS;59A%>/:'P@_[!/DN M01X)\O^6N!.3)W\E(9N>2C!=G":+:CVJ.,D;[SJP=S2^R>_P>=H?F.FXLNBB MG7_9V/]6:P=>2G+C1ZCW'VPU!+0N'-_[LYG';#:<'I8?1-9O7/T"4$L#!!0 M ( $>(@5!-[1; KP$ -(# 8 >&PO=V]R:W-H965T&UL?5-M;YPP#/XK47Y ?S8V\[P^,N:H#Q=V-Z4'CG\98Q3VZMF6N MM\#K"%*2I;O=+5-<:%KF,7:R96X&+X6&DR5N4(K;UR-(,Q8TH=? HV@['P*L MS'O>PC?PW_N318\M++50H)TPFEAH"GJ?'(Y9R(\)/P2,;F63T,G9F*?@?*X+ MN@N"0$+E P/'XP(/(&4@0AG/,R==2@;@VKZR?XR]8R]G[N#!R)^B]EU![RBI MH>&#](]F_ 1S/^\HF9O_ A>0F!Z48(W*2!>_I!J<-VIF02F*OTRGT/$<9_XK M;!N0SH#T#8!-A:+R#]SS,K=F)'::?<_#%2>'%&=3A6 <1?R'XAU&+V62)3F[ M!*(YYSCEI.N<)8,A^U(BW2IQ3/^"I]OP_:;"?83O_U#X#X)LDR"+!-E_6]S* MV;\IPE8S56#;N$V.5&;0<9-7T65A[]-X)[_3IVW_RFTKM"-GX_%FX_P;8SR@ ME-T-KE"'#VQQ)#0^F._1MM.:38XW_?R"V/*,RU]02P,$% @ 1XB!4#AA M*3JU 0 T@, !@ !X;"]W;W)KU,8J[M&T#7.=!5Y%D)(LV6RN MF>)"TR*+OI,M,M-[*32<+'&]4MS^.H(T0TZW],/Q))K6!PR M:+&9I1(*M!-&$PMU3N^VAV,:XF/ BX#!+?Y@_Q)KQUK.W,&]D:^B\FU.;RFIH.:]]$]F^ I3 M/7M*IN(?X0(2PX,2S%$:Z>)*RMYYHR86E*+X^[@+'?=AO-GO)]@Z()D R0RX MC7G8F"@J?^">%YDU [%C[SL>GGA[2+ W97#&5L0[%._0>RFV:9JQ2R":8HYC M3+*,F2,8LL\IDK44Q^0?>+(.WZTJW$7X[@^%^W6"=)4@C03I?TM(T.5*:7L=)7GCG@;U+XIM\AH_3_IW;1FA'SL;CR\;^U\9X0"F;*QRA M%C_8;$BH?3C>X-F.8S8:WG33#V+S-RY^ U!+ P04 " !'B(%0^)/,P+0! M #2 P &0 'AL+W=OUUKX =]Q[]^XXL@'- MLVT!''E14MN%DB.V5XN;U"!*'G&[IF^-)-*T+#E9D'6_@.[@?WCFF(CP$_!0QV<2:ADC/B'P#:9ZKBF9 MBG^ "T@?'I3X'"5*&U=2]M:AFEB\%,5?QEWHN _CS74RP=8!R01(9L ^YF%C MHJC\"W>\R P.Q(R][WAXXNTA\;TI@S.V(MYY\=9[+\4VOJK M-'&:+"FQUW&2%]YY8&_C([*_X>.T/W+3"&W)&9U_V=C_&M&!E[*Y\B/4^@\V M&Q)J%XXW_FS&,1L-A]WT@]C\C8L_4$L#!!0 ( $>(@5#6$N]WLP$ -(# M 9 >&PO=V]R:W-H965T,;NB[X[&M&Q<<+$\[4<,3N._=R7B+S2QEJT#; M%C4Q4&7T=G,X[D)\#/C1PF 79Q(J.2,^!^-KF=$D" ()A0L,PF\7N ,I Y&7 M\6OBI'/* %R>W]D_Q]I]+6=AX0[ES[9T349O*"FA$KUTCSA\@:F>/253\=_@ M M*'!R4^1X'2QI44O76H)A8O18F7<6]UW(?QYGH_P=8!? +P&7 3\[ Q451^ M+YS(4X,#,6/O.Q&>>'/@OC=%<,96Q#LOWGKO)=_LDY1= M$4 M?4[!UU(<^3]PO@[?KBK<1OCV#X7_R;];)=A%@MV'):[%_*V2+7JJP-1QFBPI ML-=QDA?>>6!O>7R3W^'CM#\(4[?:DC,Z_[*Q_Q6B R\EN?(CU/@/-AL2*A>. MG_S9C&,V&@Z[Z0>Q^1OG;U!+ P04 " !'B(%0_X8EL;0! #2 P &0 M 'AL+W=OY>F3=ID_WT!/6M;:]>3,,^8CFV78 CKPHJ6U! M.^?Z$V.VZD!Q>X<]:'_3H%'<>=.TS/8&>!U!2K)DMWO'%!>:EGGT74R9X^"D MT' QQ Y*\+Q(\SU'"B9B_\,-Y ^/"CQ M.2J4-JZD&JQ#-;-X*8J_3+O0<1^GF_0XP[8!R0Q(%L QYF%3HJC\D3M>Y@9' M8J;>]SP\\?Z4^-Y4P1E;$>^\>.N]MW)_2'-V"T1SS'F*2=8Q2P3S[$N*9"O% M.?D/GFS#TTV%:82G?RG,M@FR38(L$F1OEK@5<_@G"5OU5(%IXS194N&@XR2O MO,O WB?Q3?Z$3]/^A9M6:$NNZ/S+QOXWB Z\E-V='Z'.?[#%D-"X<'SOSV8: ML\EPV,\_B"W?N/P-4$L#!!0 ( $>(@5 #@=?&M $ -(# 9 >&PO M=V]R:W-H965T0-DAIUMZ<[S(I@W1P8JL$PU\@?"U.SNTV,Q220W&2VN(@SJG3]OC M:1_C4\ W"8-?G$FLY&+M:S0^5CG=1$&@H R10>!VA6=0*A*AC!\3)YU31N#R M?&-_GVK'6B["P[-5WV45VIP>**F@%KT*+W;X %,]]Y1,Q7^"*R@,CTHP1VF5 M3RLI>Q^LGEA0BA9OXRY-VH?Q9G>#K0/X!. SX) ;$R4E+\30129LP-Q8^\[ M$9]X>^38FS(Z4RO2'8KWZ+T6V_N'C%TCT11S&F/X,F:.8,@^I^!K*4[\'SA? MA^]6%>X2?/>'PL=U@OTJP3X1[/];XEK,X:\D;-%3#:Y)T^1):7N3)GGAG0?V MB:&UL?5/;;MP@$/T5Q <$K[W9IBO;4C91U4JMM$K5 M])FUQS8*,"[@=?KW!>RX5FOE!9CAG#,7AGQ$\V([ $=>E=2VH)US_9$Q6W6@ MN+W!'K2_:= H[KQI6F9[ [R.)"59FB0'IKC0M,RC[VS*' -H'? 0\ M"QCMZDQ")1?$EV!\J0N:A(1 0N6" O?;%1Y RB#DT_@U:](E9""NSV_JGV+M MOI8+M_" \J>H75?0.TIJ:/@@W1..GV&NYY:2N?BO< 7IX2$3'Z-":>-*JL$Z M5+.*3T7QUVD7.N[C=)-E,VV;D,Z$="'?4E1+H5XI3^1T^WZ=EF MAEFD9^OHAV1;8+\IL(\"^W=+W, <_BV2K7JJP+1QFBRI<-!QDE?>96#OT_@F M?^'3M'_CIA7:D@LZ_[*Q_PVB Y]*&UL?5-A;]P@#/TKB!]0[KBLK4Y)I%ZG:9,VZ=1IZVM3*NH)WW_9$Q5W6@A;O! M'DRX:=!JX8-I6^9Z"Z).(*T8W^UNF1;2T#)/OK,M$1E(I$0<:/F9,N*2-P?7YC_Y!J#[5< MA(-'5,^R]EU![RFIH1&#\D\X?H2YGG>4S,5_ABNH$!Z5A!P5*I=64@W.HYY9 M@A0M7J==FK2/TPV_FV'; #X#^ *X3WG8E"@I?R^\*'.+([%3[WL1GWA_Y*$W M572F5J2[(-X%[[7(@5 =NP9@M $ -(# 9 >&PO=V]R:W-H965T- ML8I[-&W+7&^!UQ&D)$MWNP-37&A:YM%WMF5N!B^%AK,E;E"*VU\GD&8L:$+? M'$^B[7QPL#+O>0O?P'_OSQ8MMK#40H%VPFABH2GH?7(\[4-\#/@A8'2K,PF5 M7(QY"<;GNJ"[( @D5#XP<-RN\ !2!B*4\7/FI$O* %R?W]@_QMJQE@MW\&#D MLZA]5] [2FIH^"#]DQD_P5S/+25S\5_@"A+#@Q+,41GIXDJJP7FC9A:4HOCK MM L=]W&ZR9(9M@U(9T"Z .YB'C8EBLH?N>=E;LU([-3[GH(?B'7JO97*XS=DU$,TQIRDF7<*K!MG"9'*C/H.,DK[S*P]VE\D_?P:=J_'S9V/_&& \H97>#(]3A!UL,"8T/QP]XMM.8388W_?R#V/*-R]]02P,$ M% @ 1XB!4"02BI"T 0 T@, !D !X;"]W;W)K&UL?5-A;]L@$/TKB!]0$I*U661;:CI-F[1)4:=MGXE]ME&!\P#'W;\? M8-?S6FM?@#ONO7MW'-F ]LFU )X\:V5<3EOONR-CKFQ!"W>#'9AP4Z/5P@?3 M-LQU%D250%HQOMG<,BVDH466?&=;9-A[)0V<+7&]UL+^/H'"(:=;^N)XE$WK MHX,562<:^ ;^>W>VP6(S2R4U&"?1$ MU3N^WQ],^QJ> 'Q(&MSB36,D%\2D: MGZN<;J(@4%#ZR"#"=H4'4"H2!1F_)DXZIXS Y?F%_6.J/=1R$0X>4/V4E6]S M>J"D@EKTRC_B\ FF>MY1,A7_!:Z@0GA4$G*4J%Q:2=D[CWIB"5*T>!YW:=(^ MC#><3[!U )\ ? 8<4AXV)DK*/P@OBLSB0.S8^T[$)]X>>>A-&9VI%>DNB'?! M>RVVMW<9NT:B*>8TQO!ES!S! ON<@J^E./$W<+X.WZTJW"7X[A^%AW6"_2K! M/A'L_UOB6LS[5TG8HJ<:;).FR9$2>Y,F>>&=!_8^/2+[&SY.^U=A&VD/Q+ISM.&:CX;&;?A";OW'Q!U!+ P04 M" !'B(%008W+%EM8*JFA<])TQ$*=T[O=X9B&^!CP4\+H5F<2*CD;\Q2,+U5. MDR (%)0^, C<+G /2@4BE/$\<](E90"NSZ_LGV+M6,M9.+@WZE%6OLWI+245 MU&)0_L&,GV&NYP,E<_%?X0(*PX,2S%$:Y>)*RL%YHV<6E*+%R[3++N[C=)/N M9]@V@,\ O@!N8QXV)8K*/PHOBLR:D=BI][T(3[P[<.Q-&9RQ%?$.Q3OT7HK= M39*Q2R":8XY3#%_'+!$,V9<4?"O%D?\%Y]OP_:;"?83OWRC\1_YTDR"-!.E_ M2]R*>:^2K7JJP39QFAPIS=#%25YYEX&]X_%-_H1/T_Y-V$9VCIR-QY>-_:^- M\8!2DBL&UL?5-A M;]L@$/TKB!]0$L=9J\BVU'2:-FF3HE9;/Q/[;*,"YP&.NW]?P([G=M:^ '?< M>_?N.+(!S8MM 1QY55+;G+;.=0?&;-F"XO8&.]#^ID:CN/.F:9CM#/ J@I1D MR6;SB2DN-"VRZ#N9(L/>2:'A9(CME>+FSQ$D#CG=TJOC432M"PY69!UOX G< MS^YDO,5FEDHHT%:@)@;JG-YO#\ 7P(&NSB34,D9\248WZJ<;H(@D%"Z MP,#]=H$'D#(0>1F_)TXZIPS Y?G*_B76[FLY\R P.Q(R][WAXXNTA\;TI@S.V(MYY\=9[+\7V=I>Q2R": M8HYC3+*,F2.89Y]3)&LICLD_\&0=OEM5N(OPW3N%Z3I!NDJ01H+TOR6NQ>P_ M)&&+GBHP39PF2TKL=9SDA7<>V/LDOLG?\'':?W#3"&W)&9U_V=C_&M&!E[*Y M\2/4^@\V&Q)J%XZW_FS&,1L-A]WT@]C\C8LW4$L#!!0 ( $>(@5".+/WO MM0$ -(# 9 >&PO=V]R:W-H965T0=DAIUOZYGB631NB@Q59)QKX N%K=W%H ML9FEDAJ,E]80!W5.'[>G\S[&IX!O$@:_.)-8R=7:EVA\K'*ZB8) 01DB@\#M M!D^@5"1"&3\F3CJGC,#E^8W]?:H=:[D*#T]6?9=5:'-ZI*2"6O0J/-OA TSU MW%,R%?\);J P/"K!'*55/JVD['VP>F)!*5J\CKLT:1_&FWL^P=8!? +P&7!, M>=B8*"E_)X(H,F<'XL;>=R(^\?;$L3=E=*96I#L4[]%[*[:'AXS=(M$4D?T.'Z?]LW"--)Y<;<"73?VOK0V 4C9W.$(M M?K#94%"'>#S@V8UC-AK!=M,/8O,W+GX!4$L#!!0 ( $>(@5 ,E4UCM0$ M -(# 9 >&PO=V]R:W-H965T=6J=1EMO.\.C+FB 2WF@Q9O*6"T\FK9FKK,@RDC2BO$D^<*TD"W- MT^@[V3PUO5>RA9,EKM=:V+]'4&;(Z(:^.9YDW?C@8'G:B1I^@O_5G2Q:;%8I MI8;62=,2"U5&[S:'XR[@(^!9PN 69Q(J.1OS$HQO94:3D! H*'Q0$+A=X!Z4 M"D*8QI])D\XA W%Y?E-_C+5C+6?AX-ZHW[+T34;WE)10B5[Y)S-\A:F>:TJF MXK_#!13"0R88HS#*Q944O?-&3RJ8BA:OXR[;N _C#;^=:.L$/A'X3-C'.&P, M%#-_$%[DJ34#L6/O.Q&>>'/@V)LB.&,KXATF[]![R3>.>!O>/Q3?[#QVG_(6PM6T?.QN/+QOY7QGC 5)(K'*$&/]AL M**A\.-[@V8YC-AK>=-,/8O,WSO\!4$L#!!0 ( $>(@5!-3S!&PO=V]R:W-H965T]PD07? M21>9&JS@'9PT,H.43/\Y@E!CCK?XW?'$F]9Z!RFRGC7P$^RO_J2=11:6BDOH M#%<=TE#G^'Y[.*8>'P"_.8QFM4>^DK-2+][X5N5XXQ," :7U#,PM%W@ (3R1 M2^-UYL2+I ]<[]_9OX;:72UG9N!!B6=>V3;'>XPJJ-D@[),:'V&N)\5H+OX[ M7$ XN,_$:91*F/!%Y6"LDC.+2T6RMVGE75C'Z>0NF^:AMC. *MB MDA2$)LD'(AE7N,AB[&R*3/=.< 5G@VPO)3._3R#TD.,-?@L\\:9U(4"*K&,- M? ?WHSL;[Y&9I>(2E.5:(0-UCA\VQU,:\!'PS&&P"QN%3BY:OP3G2Y7C)!0$ M DH7&)A?KO (0@0B7\:OB1//DB%Q:;^Q?XJ]^UXNS,*C%C]YY=H<'S"JH&:] M<$]Z^ Q3/RE&4_-?X0K"PT,E7J/4PL8O*GOKM)Q8?"F2O8XK5W$=QIV43FGK M"71*H'/"(>J042A6_I$Y5F1&#\B,9]^Q<,6;(_5G4X9@/(JXYXNW/GHM-H=] M1JZ!:,*<1@Q=8F8$\>RS!%V3.-%WZ70]?;M:X3:F;Y?J^__H[U8)=I%@]T^+ MAYL6US#WZR+IJDCZGN ^N1%9P]QV0A87)\$T\Q7%91.>I>(@OA?R% MCR/UC9F&*XLNVOGG$R^YUMJ!+R6Y\[6T?HIG1T#M@KGWMAG?\N@XW4UC2N9_ M1?$'4$L#!!0 ( $>(@5!MHS&8FP$ %L# 9 >&PO=V]R:W-H965T MU!V;&B M*_J>>):G/L0$J\M!G. 7A-_#P6'$9I96:C!>6D,<=!7]NMKMUQ&? '\DC/[* M)W&2H[4O,?C95K2(@D!!$R*#0'.!!U J$J&,?Q,GG5O&PFO_G?U[FAUG.0H/ M#U;]E6WH*WI/20N=.*OP;,E6"/QBJ?OJ0Y^V#UQ()2 MM'C-5IIDQWRRY5/9<@&?"OA

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htm IDEA: XBRL DOCUMENT v3.20.1
Concentrations of Credit Risk and Major Customers
 9 Months Ended
Dec. 31, 2019
Risks and Uncertainties [Abstract]  
Concentrations of Credit Risk and Major Customers

13. Concentrations of Credit Risk and Major Customers

 

For the three months ended December 31, 2019 and 2018, two customers represented approximately 49% of our total revenues from discontinued operations and three customers represented approximately 66% of our total revenues, respectively.

 

For the nine months ended December 31, 2019 and 2018, three customers represented approximately 52% of our total revenues from discontinued operations and three customers represented approximately 53% of our total revenues, respectively.

 

As of December 31, 2019, we had accounts receivable-trade of approximately $100,000, or 47%, due from two customers. As of March 31, 2019, we had accounts receivable-trade of approximately $61,000, or 13%, due from one customer.

 

As of December 31, 2019 and March 31, 2019, we had approximately $343,000 due from two customers and $185,000 due from two customers, respectively, related to receivables on license fees and royalties. These amounts are classified as accounts receivable-other in our balance sheets.

XML 47 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Held for Sale Assets and Liabilities and Discontinued Operations
 9 Months Ended
Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Held for Sale Assets and Liabilities and Discontinued Operations

5. Held for Sale Assets and Liabilities and Discontinued Operations

 

On November 25, 2019, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mitsubishi Chemical Performance Polymers, Inc., a Delaware corporation (“MCPP”), pursuant to which we agreed to sell substantially all of our assets to MCPP on the terms and subject to the conditions set forth in the Purchase Agreement (the “Asset Sale”). As consideration for the Asset Sale, MCPP agreed to pay us $7,250,000. The Purchase Agreement and the consummation of the transactions contemplated thereby required us to receive the requisite approval from our stockholders. On January 21, 2020, we held a special meeting of stockholders at which time the stockholders authorized and approved the Purchase Agreement. On January 31, 2020 (the “Closing Date”), we completed the Asset Sale. In connection with the closing of the Asset Sale, MCPP paid us a cash payment of $7,250,000 of which approximately $1,150,000 was immediately disbursed to satisfy approximately $567,000 of transaction and legal costs; approximately $483,000 of facility related obligations; and $100,000 for agreed upon contingent facility maintenance costs.

 

Pursuant to the Purchase Agreement, we sold all of our inventory; property, plant and equipment; and intangible assets, including but not limited to all intellectual property, business know-how, customer lists and related contracts, and all other assets necessary to operate our advanced polymer business. All cash; accounts receivable; prepaid expenses; deposits on facility lease; accounts payable; and accrued expenses as of the Closing Date were retained by us. We believe the Asset Sale meets the accounting criteria for held for sale assets, accordingly, the following presents the components of held for sale assets as of December 31, 2019:

 

Held for Sale Assets

 

Assets of Discontinued Operations Held for Sale   December 31, 2019     March 31, 2019  
(in thousands)                
Inventories, net   $ 271     $ 248  
Property, plant and equipment, net     1,749       1,791  
Deferred financing costs, net     47       52  
Assets of discontinued operations held for sale   $ 2,067     $ 2,091  

 

We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:

 

(in thousands)   December 31, 2019     March 31, 2019  
             
Raw materials   $ 129     $ 121  
Work in progress     35       48  
Finished goods     107       79  
Total inventories, net   $ 271     $ 248  

 

We included approximately $271,000 and $248,000 of net inventory as held for sale assets as of December 31, 2019 and March 31, 2019. The net inventory held for sale was composed of the approximate following amounts:

 

Property, plant and equipment which were included in held for sale assets consist of the following:

 

(in thousands)   December 31, 2019     March 31, 2019  
             
Land   $ 500     $ 500  
Building     2,705       2,705  
Machinery, equipment and tooling     1,248       1,248  
Furniture, fixtures and office equipment     285       285  
Office equipment under capital lease     13       13  
      4,752       4,751  
Less: accumulated depreciation     (3,003 )     (2,960 )
Property, plant and equipment, net   $ 1,749     $ 1,791  

 

Our lease with the independent third-party owner of the land and building was assigned to MCPP at which time all of our obligations with respect to the lease agreement were relieved.

 

Held for Sale Liabilities

 

On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. For accounting purposes, this sale-leaseback transaction was accounted for under the financing method, rather than as a completed sale. Under the financing method, we included the sales proceeds received as a financing obligation. As of December 31, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $155,000 and $168,000, respectively. In connection with the sale of substantially all of our assets to Mitsubishi Chemical Performance Polymers, Inc. (“MCPP”), which was completed on January 31, 2020, our lease with the independent third-party owner of the building was assigned to MCPP. As a result, we recorded the aggregate financing obligation and accrued interest on financing obligation of approximately $2,141,000 and $2,154,000 was recorded as liabilities held for sale in our balance sheet. Subsequent to the January 31, 2020, we had no further obligations with respect to the lease agreement.

 

Discontinued Operations

 

As a result of the Asset Sale, we discontinued operating as a developer, manufacturer, marketer and seller of advanced polymers on the Closing Date. Subsequent to the Closing Date, we became engaged in efforts to identify an operating company to acquire or merge with through an equity-based exchange transaction that would likely result in a change in control. Accordingly, the results of our operations are reported as discontinued operations for all periods are presented below.

 

Results of Discontinued Operations   For the Three Months Ended December 31, 2019     For the Three Months Ended December 31, 2018     For the Nine Months Ended December 31, 2019     For the Nine Months Ended December 31, 2018  
(in thousands)                                
Revenues:                                
Product sales   $ 457     $ 608     $ 1,632     $ 1,564  
License and royalty fees     351       281       803       708  
Total revenues     808       889       2,435       2,272  
Cost of sales     194       259       641       670  
Gross profit     614       630       1,794       1,602  
Operating expenses:                                
Research, development and regulatory     103       77       280       253  
Selling, general and administrative     495       271       1,049       847  
Total operating expenses     598       348       1,329       1,100  
Income (loss) from discontinued operations     16       282       465       502  
Other income (expense) from discontinued operations, net:                                
Gain on disposition of sales-leaseback assets     34       382       34       382  
Interest expense     (136 )     (94 )     (370 )     (282 )
Other income (expense) from discontinued operations, net     (102 )     288       (336 )     100  
Income (loss) from discontinued operations before provision for income taxes     (86 )     570       129       602  
Provision for income taxes     -       -       -       -  
Net income (loss) from discontinued operations   $ (86 )   $ 570     $ 129     $ 602  
                                 
Net income (loss) from discontinued operations per common share:                                
Basic   $ (0.00 )   $ 0.03     $ 0.01     $ 0.03  
Diluted     (0.00 )     0.03       0.01       0.03  
                                 
Shares used in computing net income from discontinued operations per common share:                                
Basic     23,498       21,491       22,157       21,491  
Diluted     23,498       22,711       22,157       22,627  

 

Continuing Operations

 

Our loss from continuing operations represents those costs necessary to operate a public company in the approximate amount of $65,000 and $185,000 during the three and nine months ended December 31, 2019, respectively; and $54,000 and $152,000 during the three and nine months ended December 31, 2018, respectively. These costs were composed of accounting fees, professional fees, regulatory fees, board of directors fees, and director and officer liability insurance premiums.
XML 48 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Promissory Notes
 9 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Promissory Notes

9. Promissory Notes

 

On April 26, 2016, we issued a Promissory Note to Khristine Carroll, our Executive VP of Commercial Operations in the principal amount of $25,000 (the “Carroll Note”). The Carroll Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The Carroll Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the nine months ended December 31, 2019 and 2018, we repaid $15,000 and $5,000 of principal on the Carroll Note. There were no repayments made on the Carroll Note during the three months ended December 31, 2018 and as of March 31, 2019 the principal balance outstanding was $15,000. The Carroll Note was fully repaid during the three months ended June 30, 2019, accordingly, there was no principal balance outstanding as of December 31, 2019.

 

On April 26, 2016, we issued a Promissory Note to an affiliate of Michael Adams, our Chief Executive Officer (the “Affiliate”) in the principal amount of $25,000 (the “First Affiliate Note”). The First Affiliate Note was initially due on May 25, 2016 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of May 25, 2016. The First Affiliate Note bears interest at the rate of 10% per annum and all principal and accrued interest, if any, were due on demand. During the three and nine months ended December 31, 2018, there were no repayments made on the First Affiliate Note. The First Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $25,000, respectively.

 

On December 5, 2016, we issued a second additional Promissory Note to the Affiliate in the principal amount of $100,000 (the “Second Affiliate Note”). The Second Affiliate Note was initially due on June 5, 2017 and, per mutually agreement by the parties, extended for consecutive monthly periods subsequent to the initial term of June 5, 2017. The Second Affiliate Note bears interest at the rate of 12% per annum, and provided for a $3,000 commitment fee, which fee was paid in February 2017. During the three and nine months ended December 31, 2018, there were no repayments made on the Second Affiliate Note. The Second Affiliate Note was repaid in full on December 5, 2019 as discussed in more detail below. As of December 31, 2019 and March 31, 2019, the principal balance outstanding was $0 and $100,000, respectively.

 

As discussed above, the First Affiliate Note and Second Affiliate Note (collectively, the “Affiliate Notes”) were repaid on December 5, 2019. In lieu of repayment in cash, the Affiliate authorized that the principal balance due, in the aggregate amount of $125,000, be used for purposes of exercising stock options granted to Mr. Adams pursuant to our 2017 Non-Qualified Equity Incentive Plan (the “2017 Option Plan”). As a result, Mr. Adams was issued 2,083,333 shares of our common stock granted pursuant to the 2017 Option Plan. The aggregate purchase price upon exercise of these stock options was $125,000.

 

During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $0 and $1,000, respectively, on the Carroll Note. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $1,000 and $2,000, respectively, on the Carroll Note. During the three months ended December 31, 2019 and 2018, we recorded interest expense of approximately $4,000 and $4,000, respectively, on the Affiliate Notes. During the nine months ended December 31, 2019 and 2018, we recorded interest expense of approximately $10,000 and $10,000, respectively, on the Affiliate Notes.
XML 49 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation (Tables)
 9 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity

Activity under the 2003 Plan for the nine months ended December 31, 2019 is as follows:

 

    Number of Options     Weighted-Average Exercise Price per Share     Weighted-
Average Remaining Contractual
Term in Years		     Aggregate Intrinsic Value (in thousands)  
Options outstanding as of April 1, 2019     1,788,750     $ 0.20       2.03     $ 20  
Granted     -                          
Exercised     (656,250 )                        
Cancelled or forfeited     (722,500 )   $ 0.29                  
Options outstanding as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  
Options exercisable as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  
Options vested or expected to vest as of December 31, 2019     410,000     $ 0.27       0.23     $ 1  
Schedule of Black-Scholes Pricing Model Assumptions

In determining the fair value of the options granted pursuant to the 2017 Plan, we utilized the Black-Scholes pricing model utilizing the following assumptions:

 

    August 17, 2017 Option Grants     August 16, 2018 Option Grants     December 13, 2018 Option Grants  
Total shares granted     5,600,000       750,000       200,000  
Option exercise price per share   $ 0.06     $ 0.040     $ 0.060  
Grant date fair market value per share   $ 0.06     $ 0.046     $ 0.059  
Expected term of option in years     10.0       2.00       1.00  
Expected volatility     100 %     100 %     100 %
Expected dividend rate     0.00 %     0.00 %     0.00 %
Risk free interest rate     1.00 %     0.00 %     2.69 %
XML 50 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Held for Sale Assets and Liabilities and Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Total revenues $ 808 $ 889 $ 2,435 $ 2,272
Cost of sales 194 259 641 670
Gross profit 614 630 1,794 1,602
Research, development and regulatory 103 77 280 253
Selling, general and administrative 495 271 1,049 847
Total operating expenses 598 348 1,329 1,100
Income (loss) from discontinued operations 16 282 465 502
Gain on disposition of sales-leaseback assets 34 382 34 382
Interest expense (136) (94) (370) (282)
Other income (expense) from discontinued operations, net (102) 288 (336) 100
Income (loss) from discontinued operations before provision for income taxes (86) 570 129 602
Provision for income taxes
Net income (loss) from discontinued operations $ (86) $ 570 $ 129 $ 602
Net income (loss) from discontinued operations per common share: Basic $ (0.00) $ 0.03 $ 0.01 $ 0.03
Net income (loss) from discontinued operations per common share: Diluted $ (0.00) $ 0.03 $ 0.01 $ 0.03
Shares used in computing net income from discontinued operations per common share: Basic 23,498 21,491 22,157 21,491
Shares used in computing net income from discontinued operations per common share: Diluted 23,498 22,711 22,157 22,627
Product Sales [Member]        
Total revenues $ 457 $ 608 $ 1,632 $ 1,564
License and Royalty Fees [Member]        
Total revenues $ 351 $ 281 $ 803 $ 708
XML 51 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]        
Operating expenses $ (65) $ (54) $ (185) $ (152)
Loss from continuing operations before provision for income taxes (65) (54) (185) (152)
Provision for income taxes
Loss from continuing operations (65) (54) (185) (152)
Income (loss) from discontinued operations, net of income taxes (86) 570 129 602
Net income (loss) $ (151) $ 516 $ (56) $ 450
Income per common share - basic:        
Continuing operations $ (0.00) $ (0.01) $ (0.01) $ (0.01)
Discontinued operations 0.00 0.03 (0.01) 0.03
Net income per share - basic (0.01) 0.02 0.00 0.02
Income per common share - diluted:        
Continuing operations (0.00) 0.00 (0.01) (0.01)
Discontinued operations 0.00 0.03 (0.01) 0.03
Net income per share - diluted $ (0.01) $ 0.02 $ 0.00 $ 0.02
Shares used in computing net income per common share:        
Basic 23,498 21,491 22,157 21,491
Diluted 23,498 22,711 22,157 22,627
XML 52 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Going Concern
 9 Months Ended
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

2. Going Concern

 

Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At December 31, 2019, we recorded our normal business operations as discontinued operations as a result of the previously described Asset Sale. Within ninety (90) days of the Closing Date, the Board of Directors is expected to declare a distribution of the net proceeds from the Asset Sale, after making adjustments for (i) collection of accounts receivable retained as of January 31, 2020, (ii) payment of accounts payable assumed as of January 31, 2020; and (iii) retention of a reasonable amount of cash for anticipated future obligations. As a result, we expect our funds will not be sufficient to meet our needs for more than twelve months from the date of issuance of these financial statements. Accordingly, management believes there is substantial doubt about our ability to continue as a going concern.

 

Management is seeking to identify an operating company for the purpose of effecting a merger or business combination, or to acquire assets or shares of an entity actively engaged in a business that generates sustained revenues. Although we have investigated certain opportunities to determine whether they would have the potential to add value to us for the benefit of our stockholders, we have not yet entered into any binding arrangements.

 

We do not intend to restrict our consideration to any particular business or industry segment. Because we have limited resources, the scope and number of suitable candidates to merge with is relatively limited. Because we may participate in a business opportunity with a newly formed firm, a firm that is in the development stage, or a firm that is entering a new phase of growth, we may incur further risk due to the inability of the target’s management to have proven its abilities or effectiveness, or the lack of an established market for the target’s products or services, or the inability to reach profitability in the next few years.

 

Any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to our present stockholders. As it is expected that the closing of such a transaction will result in a change in control, such transaction is expected to be accounted for as a reverse merger, with the operating company being considered the legal acquiree and accounting acquirer, and we would be considered the legal acquirer and the accounting acquiree. As a result, at and subsequent to closing of any such transaction, the financial statements of the operating company would become our financial statements for all periods presented.
XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}